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resumo 
 
 
A poliadenilação é um passo de processamento fundamental da maturação 
do mRNA, essencial para o seu transporte, estabilidade e tradução. Análises 
bioinformáticas têm demonstrado que cerca de 70% dos genes humanos 
têm vários sinais de poliadenilação na região 3’ não traduzida (3’UTR). 
Estes sinais são usados para produzir várias isoformas de mRNA por 
poliadenilação alternativa (APA), um processo com um papel fundamental 
na expressão génica em programas celulares bem como em condições 
patológicas e não patológicas. Quando ocorre na região 3’ não traduzida, a 
APA dá origem a transcritos com diferentes tamanhos da 3’UTR. Os 
microRNAs (miRNAs) e as proteínas que se ligam ao RNA (RBPs) ligam-se 
frequentemente a sequências presentes nesta região e portanto isoformas 
de mRNA com 3’UTRs mais longas contêm mais locais onde estes 
reguladores se podem ligar e, por isso, estão mais sujeitos a regulação. Os 
miRNAs são reguladores pós-transcricionais da expressão génica com cerca 
de 23 nucleótidos, que têm sido envolvidos numa variedade de condições 
celulares. No sistema imune, tem sido demonstrado que após activação dos 
linfócitos T passa a haver uma maior seleção dos sinais de poliadenilação 
proximais em vez dos distais, originando mRNAs com 3’UTRs mais curtas e 
consequentemente com menos locais onde se possam ligar miRNAs e 
RBPs. O gene MCL1 (Myeloid Cell Leukemia Sequence 1) codifica uma 
proteína (Mcl-1) com função anti-apoptótica essencial para o 
desenvolvimento e manutenção dos linfócitos T em animais, que faz parte 
da família proteica da Bcl-2, uma família de reguladores da apoptose. Tem 
sido demonstrado que o MCL1 é altamente regulado tanto ao nível 
transcricional como pós-transcricional. Os objetivos do nosso estudo são 
determinar o padrão de APA que ocorre no MCL1 em linfócitos T humanos e 
caracterizar o papel dos miRNAs na regulação das isoformas de mRNA do 
MCL1 produzidas por APA. Verificamos que o MCL1 produz quatro 
isoformas de mRNA pelo uso de quatro sinais de poliadenilação canónicos 
localizados na 3’UTR e que esses sinais são altamente conservados nos 
mamíferos. Observamos que a isoforma de mRNA mais longa é regulada ao 
nível pós-transcricional nos PBMCs ativados. Nos nossos resultados 
demonstramos também que as 3’UTR mais curtas dão origem a uma maior 
actividade de luciferase do que o mRNA mais longo. Isto sugere que durante 
a ativação dos PBMCs o aumento na proteína Mcl-1 é devida à tradução das 
isoformas mais curtas. Na segunda parte do estudo identificamos o miRNA-
17 como um possível regulador da isoforma longa após ativação dos 
linfócitos T. A expressão deste miRNA está aumentada após ativação dos 
linfócitos T e quando é mutado o seu local de ligação ao mRNA putativo na 
3’UTR do MCL1 observou-se um aumento na atividade da Luciferase na 
linha celular HeLa. Também realizamos a sobreexpressão do miRNA-17, do 
miRNA-29b e do miRNA-92a o que levou a uma diminuição na expressão 
endógena do Mcl-1. A partir deste estudo concluímos que a isoforma do 
MCL1 gerada por APA mais longa é regulada negativamente ao nível pós-
transcricional após ativação celular de modo a aumentar a expressão do 
Mcl-1 e que o miRNA-17 poderá ser o regulador chave deste mecanismo. 
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abstract 
 
Polyadenylation is a fundamental processing step of mRNA maturation, 
essential for its export, stability and translation. Bioinformatic analyses have 
shown that 70% of human genes have several polyadenylation signals (pA 
signals) in the 3’untranslated region (3’UTR) that are used to produce 
multiple mRNA isoforms by alternative polyadenylation (APA). This process 
has a fundamental role in gene expression in a variety of cellular programs 
as well as in non-pathological conditions and diseases. When it occurs in the 
3’UTR, APA gives rise to transcripts with different 3’UTR lengths. MicroRNAs 
(miRNAs) and RNA-binding proteins (RBPs) often bind to sequences present 
in that region and thus mRNA isoforms with longer 3’UTRs have more sites 
where these regulators can bind, being more prone to regulation. miRNAs 
are 23 nucleotides in length post-transcriptional regulators of gene 
expression that have been implicated in a variety of cell conditions. In the 
immune system, it has been shown that upon T cell activation there is a 
global switch in pA signal selection from a distal to a proximal pA signal, 
originating mRNAs with shorter 3’UTRs and, consequently, with less miRNAs 
and RBPs target sites. The MCL1 (Myeloid Cell Leukemia Sequence 1) gene 
encodes an anti-apoptotic protein (Mcl-1), which is a member of the Bcl-2 (B 
cell lymphoma-2) family of apoptosis regulators. MCL1 is essential for 
development and maintenance of both B and T lymphocytes in animals. It 
has been demonstrated that MCL1 is highly regulated at both transcriptional 
and post-transcriptional levels. The aims of our study were to characterize 
the pattern of MCL1 APA and to unravel the role of miRNAs in the regulation 
of MCL1 APA-derived isoforms. We discovered that MCL1 produces four 
mRNA isoforms by the usage of four canonical pA signals located in the 
3’UTR and that these pA signals are highly conserved in mammals. We 
verified that the longest mRNA isoform is regulated at a post-transcriptional 
level in activated PBMCs. We also demonstrated that the shortest 3’UTRs 
give rise to higher amounts of luciferase activity than the longest mRNA. 
Additionally, we showed that Mcl-1 protein levels increase upon PBMCs 
activation. This suggests that during PBMCs activation the increase in Mcl-1 
protein is due to the translation of the shortest isoforms. In the second part of 
this study we identified miRNA-17 as a putative regulator of the longest 
isoform upon T cell activation. The expression of this miRNA increased upon 
activation of T cells and when we mutated its putative-binding site on MCL1 
3’UTR we observed an increase in luciferase activity in HeLa cells. We also 
overexpressed miRNA-17, miRNA-29b and miRNA-92a and showed that this 
causes a decrease in endogenous Mcl-1 expression. From this study we 
conclude that the MCL1 longest APA-derived isoform is down-regulated at a 
post-transcriptional level upon T cell activation in order to increase Mcl-1 
expression and that miRNA-17 may be the key regulator in this mechanism. 
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Gene Expression 
Gene expression is a biological process highly regulated at multiple steps. 
These steps include modulation of the chromatin structure by the interaction of 
regulatory proteins with specific DNA motifs of the target genes, and also messenger 
RNA (mRNA) synthesis and processing in the nucleus, mRNA transport, and ultimately 
translation and decay of the mRNA in the cytoplasm.1, 2 These steps, in which 
information flows from DNA to RNA (transcription and precursor mRNA (pre-mRNA) 
processing) and finally to protein (translation and mRNA decay), are remarkably 
elaborate and highly interconnected in eukaryotic cells (figure 1).3, 4  
Pre-mRNA processing is a complex mechanism crucial to mRNA metabolism. 
The RNA molecule resulting from transcription (pre-mRNA) contains both coding and 
non-coding sequences. Before it can be translated into protein, introns have to be 
removed (splicing) and both ends of the pre-mRNA are modified by capping on the 5’-
end and polyadenylation on the 3’-end. These processes are known as post-
transcriptional events and occur co-transcriptionally being also highly regulated and 
interconnected. Thus, it is now well-stablished that pre-mRNA processing regulates 
downstream events affecting the fate of the transcript and thus modulating gene 
expression.5-8  
Figure 1 - Schematic illustration of the steps from DNA transcription to protein translation in 
eukaryotes. The mechanisms by which a protein is produced starts with transcription of DNA by 
RNA polymerase II to produce a pre-mRNA. Before it can be translated into a protein, the pre-mRNA 
has to be processed, forming the mature RNA that is transported to the cytoplasm where translation 
takes place. The mechanisms of RNA processing include 5’ capping, splicing and 3’ polyadenylation. 
Adapted from Alberts et al.6 
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Polyadenylation 
Polyadenylation is a pre-mRNA 3’end processing step that consists in the 
addition of a polyA (pA) tail9 by polyA polymerase (PAP) upon an endonucleolytic 
cleavage of the transcript.10-12 The length of the pA tail (about 250-300 adenines in 
humans) is crucial for the transport of mature mRNAs to the cytoplasm, their translation 
efficiency and for the quality control and degradation of mRNAs.1, 9, 11 As reviewed in 
Curinha et al.1, recent studies have now challenged what is known about the length of 
the pA tail. The pA tail is a dynamic region of the mRNA13 that is controlled differently 
depending of the developmental stage. Also, it has been shown that an increase in 
PAP activity is associated with poor prognosis in certain cancers14 and also that usage 
of PAP inhibitors affect some genes involved in inflammatory conditions15. Thus, a tight 
control of the pA tail length may be a determinant factor in the development of some 
diseases.   
Several cis- and trans-acting RNA elements (sequences in the 3’ untranslated 
region (3’UTR) of the pre-mRNA and molecules that bind to these sequences, 
respectively) are core components of the polyadenylation process. The most important 
cis-acting element is a hexanucleotide sequence, which is known as the 
polyadenylation signal (pA signal) located 15-30 nucleotides (nt) upstream of the 
cleavage site (preferably a CA dinucleotide). The AAUAAA sequence is the canonical 
pA signal and the strongest in defining the place where polyadenylation takes place, 
but this signal can also adopt more than ten weaker variants. In order to enhance the 
cleavage efficiency, two more U or GU-rich sequences located upstream and 
downstream of the pA signal, the upstream sequence element (USE) and downstream 
sequence element (DSE), are needed.9-12 The most important trans-acting elements in 
the pA signal recognition are the cleavage and polyadenylation specificity factor 
(CPSF), which binds to the pA signal, and the cleavage stimulating factor (CstF), that 
binds to the DSE sequence. Additionally, the cleavage factors I and II (CFIm and 
CFIIm), that bind to the USE sequence and are essential for the cleavage step, the 
PAP, responsible for the pA tail addition, and the pA-binding protein (PAB), are also 
core elements of the polyadenylation machinery (figure 2).9, 12  
 
Alternative Polyadenylation 
Some protein-coding genes can harbor two or more pA signals in their 
sequences and thus polyadenylation can occur in different points of the gene, a 
process known as alternative polyadenylation (APA).9-12 Different studies have 
demonstrated a role for APA in regulating 70% of the mammalian genes, increasing 
immensely the transcriptome diversity.16, 17 The recognition of one pA signal over 
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another is due to the strength of the cis and trans-acting elements that surround each 
pA signal, the strength of the pA signal itself, and the regulation at the DNA level, such 
as chromatin remodeling and epigenetic marks (figure 3).9, 10, 12  
 
 
 
 
 
 
Figure 3 – Regulatory mechanisms of alternative polyadenylation. The production of different 
APA-derived mRNA isoforms from the same transcriptional unit is tightly regulated by trans-acting 
factors (A), such as polyadenylation and splicing factors; cis-acting sequences (B), such as RBPs 
and miRNAs-binding sites; and by chromatin remodeling (C), such as the nucleosome positioning in 
the vicinity of the polyadenylation sites (pA sites). Adapted from Giammartino et al.12 
Figure 2 - Schematic illustration of the polyadenylation core elements. The cis- and trans-acting 
elements involved in the polyadenylation process are represented. The color of the trans-acting factors and 
the cis-acting elements to which they bind are the same. Adapted from Elkon et al.9 
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The pA signals can be present in the coding or intronic region, giving rise to 
transcripts with different coding sequences and thus affecting the function of the gene, 
or be present in the 3’UTR, giving rise to transcripts with the same coding region but 
different 3’UTR lengths.9-12 In this last case, since 3’UTR harbor putative-binding sites 
for several microRNAs (miRNAs) and RNA-binding proteins (RBPs), longer 3’UTRs are 
more prone to suffer regulation affecting their stability, cellular localization and/or 
translation efficiency (figure 4). Thus, the length of the 3’ UTR affect the fate of the 
transcript produced and ultimately modulates the expression of the gene.10-12  
 
 
 
 
 
 
 
 
 
 
 
 
 
Several studies have been made in the APA field and it is now known that the 
APA pattern tends to be gene-, tissue-, or disease-specific. The usage of one pA site 
over another depends on how the regulatory features mentioned above behave in the 
type of cell where the process is occurring, in the health or disease condition that the 
organism is suffering, and ultimately, in the gene being regulated (figure 5). Some 
examples of the implications of APA in health and disease will be further described 
ahead.  
 
 
 
 
 
 
Figure 4 - Regulation of alternative polyadenylated mRNAs by cis and trans-acting factors. 
The presence of RBPs and miRNAs-binding sites in the 3’UTR of different mRNA isoforms promotes 
the binding of these regulators to their specific cis-elements and thus modulate the fate of a specific 
transcript. mRNA isoforms with longer 3’UTRs are more prone to undergo this type of regulation 
since they have more of these cis-elements present in their sequence. Adapted from Tian et al.10 
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Polyadenylation and Alternative Polyadenylation in Health and Disease 
Besides exciting results in the past few years have highlighted the crucial roles 
of APA in the control of gene expression, major efforts are needed to characterize the 
APA regulatory mechanisms in a variety of genes and its importance in health and 
disease. Several studies have reported a role for polyadenylation and APA in 
oncological, immunological, neurological and haematological diseases, as well as in 
cellular and molecular conditions important for cell homeostasis. It has been described 
a preferential usage of proximal pA signals resulting in 3’UTR shortening in proliferative 
cells, such as under activation of T lymphocytes, and in tumour cells. In contrast, in 
development, differentiation processes and neurological tissues, there is a preferential 
usage of distal pA signals which gives rise to a lengthening of the 3’UTR (figure 6).1  
Some examples reviewed in Curinha et al.1 are described below.  
An important study in proliferation field is the one made by Sandberg et al.18 in 
T lymphocytes. In this study they developed a tandem UTR length index (TLI) that 
assessed the expression of extended 3’UTR relative to total gene expression levels. 
They have found that the TLI is decreased after 48h upon activation of T lymphocytes, 
representing a decrease in the relative expression of isoforms with longer 3’UTRs. 
Additionally, it was established in the same study a negative correlation between 
proliferative index and TLI.18 As B and T lymphocyte activation is a key immune 
Figure 5 - APA in a variety of cellular and organismal events. It is well-described that the usage 
of one pA site over another is actively regulated in a cellular, health and/or disease-specific manner.  
Adapted from Lutz et al.11 
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response to several stimuli, this may represent an efficient mechanism to escape 
regulation and respond quicker when lymphocyte activation is necessary. 
 
 
 
 
 
 
 
 
 
 
 
In what concerns the oncological field, Mayr et al.19 demonstrated that besides 
nontransformed cells and cancer cells have similar proliferation rates, cancer cells tend 
to produce more levels of transcripts with shorter 3’UTRs, and thus the correlation 
between shorter 3’UTRs and cell transformation is higher than shorter 3’UTRs and 
proliferation. Also in this study it was demonstrated that isoforms with shorter 3’UTRs 
produce more protein due to its higher stability, which may be a relevant activation 
mechanism employed by some oncogenes in cancer cells. This was demonstrated 
using the proto-oncogene insulin-like growth factor 2 mRNA binding protein 1. The 
shortest mRNA isoform was shown to promote higher oncogenic transformation levels 
than its longest mRNA isoform. This could be explained by the fact that shorter 3’UTRs 
have less binding sites to negative regulators such as miRNAs and thus are less prone 
to regulation.19 Also in this field, Fu et al.20, described an opposite pattern of 3’UTR 
length in two different breast cancer cell lines. In MCF7 cell line it was seen an 
elevated production of  mRNA isoforms with shorter 3’UTRs whereas in MB231 cell line 
it was seen high production of longer 3’UTR mRNA isoforms.20 What it can be 
concluded from this observation is that in cancer, APA is regulated at a cell type-
specific manner.  
Figure 6 - APA in proliferative and developmental conditions. According to a variety of cellular 
states, as well as diverse diseases, the choice of one pA site over another is differentially regulated. 
The choice of proximal pA signals occurs preferentially in proliferative conditions and cell 
transformation while the choice of distal pA sites occurs mostly in cell differentiation and late 
developmental stages. Adapted from Di Giammartino et al.12 
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In contrast to cell proliferation and tumour cells, it has been shown that during 
development and cell differentiation there is an increase in the usage of distal PAS. 
Hoque et al.16, analyzed C2C12 and 3T3-L1 cells, which were induced to differentiate 
and represent a model for myogenesis and adipogenesis respectively, and also mouse 
embryos as a model for embryogenesis. In this study it was demonstrated an increase 
in the levels of mRNAs produced by the usage of distal PAS both in mouse embryos 
and during cell differentiation.16 
In what concerns neurological system, it has been shown that an aSyn mRNA 
isoform with a longer 3’ UTR is more highly expressed in brain tissues of Parkinson 
disease patients compared with unaffected brains.21 Another study in this field 
demonstrated that COX-2, which is expressed in the brain, produces two different 
mRNAs with 2.8 kb and 4.6 kb by APA. It has been demonstrated that the neocortex, 
which is affected in Alzheimer disease, expresses high levels of the 4.6 kb COX-2 
mRNA, and therefore a possible association between COX-2 APA pattern, its 
expression levels and Alzheimer disease phenotype may be foreseen.22 
 
Myeloid Cell Leukemia-1 gene  
Myeloid cell leukemia-1 (MCL1) gene was first described to be up-regulated in 
ML-1 cells, a human myeloid leukemia cell line, in an early differentiation stage. It 
encodes Mcl-1, a member of the B-cell lymphoma 2 (Bcl-2) protein family. The Bcl-2 
protein family is known to be involved in the regulation of apoptosis, a programmed 
form of cell death crucial for tissue homeostasis, development, inflammation and safe 
removal of unwanted or damaged cells. An aberration in this physiological event could 
lead to human disease, such as cancer, once it promotes cell immortalization. The 
regulation of apoptosis by Bcl-2 protein family members is achieved throughout the 
balance between the pro- (e.g., Bax and Bad) and anti-apoptotic proteins (e.g., Bcl-2, 
Bcl-XL and Mcl-1) of this family, which determines the flow of cells through proliferation 
and differentiation.23-26 
Mcl-1 is an anti-apoptotic protein known to provide short-term enhancement of 
cell viability influencing cell fate transitions and also life and dead-decisions. Mcl-1 
exerts its anti-apoptotic function by sequestering Bax and Bak proteins, pro-apoptotic 
members of the Bcl-2 protein family. Mcl-1 is a ubiquitous protein, however, its 
expression varies in a tissue- and differentiation-specific manner according to its 
physiological role.23-25, 27 A variety of cell types depend on Mcl-1 expression for their 
survival and development, such as B and T-lymphocytes and neutrophils. Also, it is 
described that Mcl-1 is very important for macrophage effector function.23, 25, 28 
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Contribution of Mcl-1 to T cells biology and pathophysiology  
T lymphocytes are core elements of immunity that confer specificity to the 
immune response. These cells are produced in bone marrow and mature in the thymus 
where differentiate from double negative (four stages: DN1, DN2, DN3, DN4), CD4-
CD8-, to double positive (DP), CD4+CD8+, and then to single positive (SP), CD4+CD8- 
or CD8+CD4- cells. From the thymus, SP thymocytes transit to peripheral blood where 
after activation and subsequent proliferation, differentiate from naïve T cells to effector 
T cells.29, 30 Mcl-1 is expressed by T cells at all developmental stages and is necessary 
for their survival and, consequently, their maturation.29, 31 In order to determine the role 
of Mcl-1 in T cell development and function, a variety of studies have been made and  
demonstrated the role of Mcl-1 in regulating T cells biology. For example, Opferman et 
al.31 and Dzhagalov et al.29 verified a dependence of T lymphocytes on Mcl-1 for their 
development, survival and maintenance. In the Opferman et al.31 study they used a 
knockout mouse for Mcl-1 and found a decrease in the overall expression of 
thymocytes: double positive cells and single positive cells. Also, it was demonstrated 
that the loss of Mcl-1 increased apoptosis at DN2 thymocytes and arrested the 
development of DN3 thymocytes. Moreover, in this study it was shown a role for Mcl-1 
in maintaining the existing mature T lymphocytes since the deletion of Mcl-1 lead to the 
depletion of T cells from the spleen.31 Dzhagalov et al.29 went further and demonstrated 
also a role for Mcl-1 in the survival of activated T cells and thus this study together with 
the Opferman et al.31 study demonstrates that Mcl-1 promotes the survival of DN, DP, 
SP, naïve and activated T cells. In Dzhagalov et al.29 study they confirmed that MCL1 
deletion resulted in the blockage of DN2/DN3 to DN4 transition and also in the 
decreased of SP cells. It was also demonstrated in vitro that DP cells depend on Mcl-1 
for their survival, but in vivo the loss of Mcl-1 did not have an effect in the DP survival 
cells since other anti-apoptotic molecules of this family also have important roles in the 
survival of T cells at this developmental stage. The authors also searched for the role 
of Mcl-1 in activated T cells and in contrast with DP cells in vitro, activated T cells from 
a MCL1 knockout mouse undergone apoptosis demonstrating the importance of Mcl-1 
in the maintenance of activated T cells. Also, they have stimulated T cells with an anti-
CD3 antibody, which binds to CD3 on the surface of T cells, and a strongly up-
regulation of Mcl-1 was seen, demonstrating a role for Mcl-1 in the survival and 
function of activated T cells.29 
It was also demonstrated that MCL1 has a relevant role under pathological 
conditions. Particularly, MCL1 is highly expressed in diverse human cancers with poor 
prognosis, a variety of which hematopoietic cancers, such as acute lymphoblastic 
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leukemia (ALL) and chronic lymphocytic leukemia (CLL), contributing to malignant cell 
growth and evasion of apoptosis.25 Therefore, compounds that inhibit MCL1 could be 
an efficient therapeutic agent in cancers with MCL1 overexpression. 
MCL1 gene characterization and post-transcriptional regulation 
The human MCL1 gene comprises 3 exons, all of which encode the information 
that gives rise to the anti-apoptotic protein Mcl-1. This gene is actively regulated at both 
transcriptional and post-transcriptional levels.23, 24 A variety of interleukins (IL-332, IL-
533, IL-634) as well as growth factors, such as epidermal growth factor (EGF)35 and 
vascular endothelial growth factor (VEGF)36, were described to induce transcriptional 
up-regulation of MCL1. At transcriptional level, a variety of transcription factors are 
implicated in MCL1 regulation, being the signal transducers and activators of 
transcription (STAT) an important family of these regulators. In response to IL-637, IL-
332, and VEGF38, STAT3 was described to up-regulate the transcription of this gene. 
Other transcription factors involved in MCL1 transcription regulation are the PU.139 and 
hypoxia-inducible factor 1-alpha (HIF-1α)40, described to up-regulate transcription of 
MCL1, and E2F-141, that down-regulate MCL1 through its binding to the MCL1 
promoter.23, 24, 27 
At post-transcriptional level, MCL1 is initially regulated by alternative splicing, 
which gives rise to three mRNA isoforms. By the skipping of exon 2 or by the skipping 
of a portion of exon 1, it is generated two shortened mRNA isoforms, Mcl-1S and Mcl-
1ES, respectively. Contrary to the anti-apoptotic isoform, these two alternative splicing-
derived isoforms have a pro-apoptotic role by sequestering the Mcl-1 anti-apoptotic 
isoform and because they are unable to interact and sequester the pro-apoptotic Bcl-2 
family members (figure 7). MCL1 is also down-regulated by miRNAs, being the most 
known miRNA-2923, 42, as will be further explained below. At translation level, one 
example of MCL1 regulation is by the PI3K-AKT-mammalian target of rampamycin 
complex 1 (mTORC1) pathway, which induces MCL1 translation (figure 8).23, 24, 27, 42 
 
 
 
 
 
Figure 7 - MCL1 gene characterization. In this figure the light blue boxes correspond to exons, the 
dark blue lines correspond to 5’UTR (left) and 3’UTR (right), and the green lines correspond to 
introns. MCL1 is transcribed in three mRNA isoforms; the longest mRNA produces an anti-apoptotic 
protein (Mcl-1) and the other two mRNA isoforms (MCL-1S and MCL-1ES) are generated by 
alternative splicing and encode pro-apoptotic proteins. 
MCL1ES 
MCL1S 
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MicroRNAs 
miRNAs are non-coding RNAs found in animals and plants representing a large 
family of post-transcriptional regulators of gene expression, whose mature products 
have 21 to 23 nucleotides in length.43-47 Several studies have demonstrated the 
important role of miRNAs in a wide range of biological processes like development, 
proliferation and differentiation, metabolism, apoptosis and cancer.45, 46, 48 Also, it is 
now known that a single miRNA might control numerous distinct targets and it is 
estimated that about 50% of all mammalian genes are under miRNA control.43, 48 
 The miRNAs are usually processed by RNA polymerase II from precursor 
molecules such as independent genes or introns of protein-coding genes. The product 
of RNA polymerase II (pri-miRNA) acts as a substrate for two members of RNase III 
family of enzymes, Drosha and Dicer. First, Drosha in complex with DGCR8, processes 
the pri-miRNA giving rise to a ~70-nucleotide precursor hairpin, the pre-miRNA. The 
pre-miRNA is then recognized by exportin 5 and thus exported to the cytoplasm where 
is processed by DICER, assisted by the transactivating response RNA-binding protein 
(TRBP). This leads to the formation of a ~20 nucleotide miRNA/miRNA duplex. One of 
the two strands of this complex, the mature miRNA, is then incorporated into an 
Argonaute (AGO) protein, essential for target recognition, giving rise to the miRNA-
induced silencing complex (miRISC).43, 45, 46, 48 
Figure 8 - MCL1 gene transcriptional and post-transcriptional regulation. MCL1 is 
transcriptionally and post-transcriptionally regulated by a variety of transcription factors, by miRNAs, 
such as miRNA-29b and by signalling pathways, such as the PI3K-AKT-mTORC1 pathway. Juin et 
al.24 
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 miRISC recognizes an mRNA to be silenced through the base pairing-
interactions between the miRNA and its target mRNA. The seed region, a ~8-
nucleotide motif at the 5’ domain of the miRNA, is the predominant mechanism for 
target mRNA recognition. Along the mRNA sequence there is a plenitude of regions 
where seed matches may occur, however, they are more prone to silence an mRNA 
when they are in the 3’UTR49, 50. The targets to be silenced can contain a partially or 
fully complementary sequence to the corresponding miRNAs. According to the type of 
base pairing interactions, miRNA-mediated gene silencing can occur by mRNA 
cleavage, mRNA degradation or translational repression. If the miRNA contains a fully 
complementary sequence the target will be repressed by mRNA cleavage. In contrast, 
if the miRNA contains a partially complementary sequence the mechanism of action 
will be trough translational repression or mRNA degradation.44-46 
According to a variety of studies that have been done in the past few years, 
mRNA degradation is responsible for ~75%-85% of the changes observed in protein 
synthesis, attributing a less important role of miRNAs in translational repression. 45, 47, 48 
The mechanism of mRNA degradation by miRNAs is the following: once an mRNA is 
targeted by the miRISC complex to be silenced, GW182 interacts by its amino-terminal 
domain with AGO protein and by its carboxy-terminal domain with polyA-binding 
protein, cytoplasmic 1 (PABPC1) that is bound to the pA tail of the target mRNA. Then, 
the complex AGO-GW182-mRNA leads to the removal of the pA tail (deadenylation) by 
the CAF1-CCR4-NOT deadenylase complex. This mechanism, in turns, leads to the 
decapping of the mRNA by the DCP2 enzyme and mRNA degradation by the 5’-to-3’ 
exoribonuclease 1 (XRN1).43, 48, 51 
A general overview of the miRNAs biogenesis and function described above is 
illustrated in figure 9. 
  
miRNAs in MCL1 regulation 
Several miRNAs were demonstrated to down-regulate MCL1 expression in a 
variety of human cancers. Examples of this regulation are: miRNA-135a/b in a lung 
cancer cell line52, miRNA-133a/b in human osteosarcoma53, 54, miRNA-204 in 
pancreatic cancer55, miRNA-100/99a in acute lymphoblastic leukaemia56, miRNA-193a 
in epithelial ovarian cancer cells57, miRNA-139 in glioma58, miRNA-26a in breast 
cancer59, and miRNA-29b in, for example, a glioblastoma multiforme cell line60.  
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The most well-established miRNA that regulates MCL1 expression is miRNA-
2942, 60. Aldaz et al.60  described that the overexpression of miRNA-29a and miRNA-29b 
in GN1C cells, a type of glioblastoma multiforme cell line, leads to the decrease of Mcl-
1 protein expression (54% and 62%, respectively), resulting in an increase of apoptosis 
(about 1,6-fold and 1,56-fold increase, respectively).60 In what concern cancers of the 
lymphoid lineage, Li et al.56  demonstrated a role for miRNA-100 and miRNA-99a in 
down-regulating MCL1 expression in ALL. In this study, they first demonstrated that 
both miRNAs had lower expression in acute lymphoblastic leukemia patients and that 
when they overexpressed these two miRNAs the levels of MCL1 were decreased.56  
Since MCL1 plays a major role in suppressing apoptosis, characterization of the 
MCL1 mRNA isoforms produced by APA and the miRNAs that regulate its expression 
may be a useful therapeutic tool in different clinical contexts in the future. 
 
Figure 9 - miRNAs biogenesis and function. miRNAs are transcribed in the nucleus by RNA 
polymerase II and exert their function in the cytoplasm. miRNAs regulate their targets by translation 
repression, mRNA degradation or mRNA cleavage, depending on their complementary to their 
targets. There is strong evidence that target degradation provides a major contribution to silencing by 
animal miRNAs. Adapted from Breving et al.45 
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Aims of this thesis 
Despite all the studies regarding MCL1 regulation, nothing was known about the 
role of polyadenylation and APA on MCL1 regulation. Also, post-transcriptional 
regulation of MCL1 by miRNAs in T cells in resting and activated states had not been 
previously investigated. Therefore, the main goals of this thesis were to characterize 
the APA pattern of MCL1 in primary human T cells in both resting and activated 
conditions and to identify miRNAs involved in MCL1 post-transcriptional regulation. 
 
Overall, the specific objectives of the experimental work were to: 
 Map the mRNAs 3’ ends of MCL1 produced by APA; 
 Determine the MCL1 APA-derived mRNA isoforms expression both at mRNA 
and protein level. 
 Identify the miRNAs that could influence MCL1 expression in T cells; 
 Quantify the expression of potential miRNAs in primary human T cells; 
 Analyse the effect of mutations of the putative miRNA-binding sites on MCL1 
3’UTR ; 
 Study the consequences of miRNAs overexpression in the expression of Mcl-1 
protein; 
 Identify a miRNA that affects MCL1 expression and that could be used as a 
potential therapeutic target in the future. 
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IN SILICO ANALYSIS  
In order to check for MCL1 coding and 3’UTR sequences and for predicted APA 
pattern we used the UCSC genome browser. To assess the conservation of the 3’UTR, 
the pA signals and the putative-binding sites of the chosen miRNAs we performed a 
multiple sequence alignment of the mRNA or genomic sequence of ten mammalian 
species using the default settings of the MUSCLE 3.6 software running on Geneious 
program v4.8. 
To search for miRNAs putative-binding sites on MCL1, TargetScan 
(https://www.targetscan.org/), microRNA.org (https://www.microRNA.org/) and 
miRTarBase (https://www.mirtarbase.mbc.nctu.edu.tw/) databases were assessed 
using the default settings. The microRNA.org database and miRNAmap 
(https://www.mirnamap.mbc.nctu.edu.tw/) databases were used to determine the 
expression of the miRNAs in different tissues. 
 
EXPERIMENTAL MODELS 
Cell culture 
Jurkat E6.1 cell line was grown and maintained in culture at 37 ºC with 5% CO2 
atmosphere in complete medium (RPMI 1640 medium modified with GlutaMAX and 
phenol red, 10% fetal bovine serum (FBS) and 1% of a penicillin/streptomycin antibiotic 
solution). Cells were split every 3-4 days in order to be at a concentration around 2 x 
106 cells/mL.  
HeLa cell line was also grown and maintained in culture at 37 ºC with 5% CO2 
atmosphere in complete medium (DMEM with 10% FBS and 1% of a 
penicillin/streptomycin antibiotic solution). Cells were split in a 1:10 ratio every 3-4 days 
to maintain subconfluency. 
All the reagents mentioned above are from Gibco®, Life technologies. 
Human PBMCs and T cells isolation 
Human blood buffy coats were obtained from volunteer blood-donors from 
Hospital de São João. Peripheral blood mononuclear cells (PBMCs) were isolated 
using Lympholyte®-H (Cedarlane Labs) according to the manufacturer’s 
instructions.  
In order to isolate T lymphocytes, previously isolated PBMCs were 
resuspended in 1X PBS (phosphate-buffered saline) at approximately 5x107 
cells/mL and the EasySep negative selection kit (STEMCELL technologies) was 
used. Using this kit the unwanted cells (using antibodies CD14, CD16, CD19, 
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CD20, CD36, CD56, CD66b and CD123) are retained using magnetic beads while 
T cells are enriched by separating the desire fraction into a new tube.  
Both PBMCs and T cells were counted using an automated cell counter 
(Countess®, Life Technologies) and cultured at 1 x 106 cells/mL in RPMI complete 
medium. 
Cell Activation 
Both primary PBMCs and human T cells were activated with 
phytohemagglutinin (PHA) in a final concentration of 1 µg/mL for 48 hours. Cells in 
resting and activated states were harvested for further RNA extraction. 
 
QUANTITATIVE MRNA EXPRESSION ANALYSIS 
RNA fractionation 
PBMCs were collected, washed twice with 1X PBS and resuspended in 1 
mL of RSB buffer (10 mM Tris pH 7.4, 10 mM NaCl and 3 mM MgCl2). After 3 min 
incubation on ice, cells were centrifuged at 3200 g for 3 min at 4 ºC, and the 
supernatant was discarded. The pellet was resuspended in 150 µL of RSBG40 
buffer (10 mM Tris pH 7.4, 10 mM NaCl, 3 mM MgCl2, 10% glycerol, 0.5% NP-40, 
0.5 mM DTT (Invitrogen) and 40U/L RiboLock RNase Inhibitor (Thermo 
Scientific)). Cells were centrifuged at 4500 g for 3 min at 4 ºC. Upon supernatant 
(the cytoplasmic fraction) had been transferred to a new eppendorf, it was added 1 
mL of TRIzol to the supernatant and to the pellet (nuclear fraction). The RNA 
extraction was then performed as described bellow. 
RNA extraction 
Total RNA was extracted with TRIzol reagent (Invitrogen) following the 
manufacturer standard protocol. First we added 1 mL of TRIzol reagent and incubated 
5 min at room temperature. Then 200 µL of chloroform was added and the samples 
were mixed and centrifuged for 15 min at 12000g at 4ºC. The upper aqueous phase 
was transferred to a fresh tube containing 1 µL of Glicoblue (15mg/mL, Life 
Technologies) and the same amount of isopropanol as the aqueous phase transferred. 
The samples were mixed and then frozen overnight at -80ºC. In the next day, after 
thawing, samples were centrifuged for 20 min at 12000g at 4ºC following by a pellet 
washing step with 500 µL of 75% cold ethanol centrifuged 10 min at 12000g at 4ºC . 
The pellet was air dried and resuspended in 11 µL of Nuclease-free water (Thermo 
Scientific).  
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Total RNA enriched with small RNAs extraction was performed using the 
mirVanaTM isolation kit protocol (Ambion, Life Technologies). Primary T cells and/or 
Jurkat E6.1 cell line were counted as described above and 102 to 107 cells were 
pelleted and further washed using 1mL of cold PBS 1X. HeLa cells were 
trypsinized, counted and then 102 to 107 cells were pelleted and further washed 
using 1 mL cold PBS 1X.  After cell suspension preparation the RNA extraction 
was performed according to the manufacturer’s instructions with minor 
modifications. The first wash step using miRNA Wash Solution 1 was divided in 
two steps: instead of using 700 µL of this solution and centrifuged once, we added 
350 µL twice and centrifuged each time performing the DNase (DNase I 
recombinant, Roche) treatment (final concentration 3 U/µL) between these two new 
steps. 
RNA quantification was performed in a NanoDropTM 1000 
Spectrophotometer (Thermo Scientific) and the RNA stored at – 80 ºC.  
DNase treatment 
DNase treatment for total RNA was performed in a final volume of 12 µL, 
the volume necessary to further perform cDNA synthesis. DNase recombinant I 
(Roche) was used at a final concentration of 1 U/µL and the samples were 
incubated at 37ºC for 90 min. Samples were then incubated 10 min at 75ºC for 
enzyme inactivation. 
cDNA synthesis 
After total RNA or fractionated RNA extraction and DNAse treatment, 
SuperScript IIITM Reverse Transcriptase enzyme (Invitrogen, Life Technologies) was 
used to synthesise cDNA from 300 ng or 500 ng of DNase treated RNA from human 
primary T cells and PBMCs or HeLa and Jurkat E6.1 cell lines, respectively, following 
the manufacture’s guidelines. Briefly, to the treated RNA was first added 1µL of dNTPs 
(10 mM) and 1 µL of random hexamers (50 µM) and the mixture was then incubated at 
65ºC for 5 min in order to denature RNA, followed by 5 min at 4ºC. The mix for reverse 
transcription was prepared at a final volume of 6 µL containing 4 µL of cDNA synthesis 
buffer (5X), 1µL of DTT (0,1 M), 0,5 µL of RiboLock RNase Inhibitor (40 U/µL, Thermo 
Scientific) and 0,5 µL of SuperScript III reverse transcriptase enzyme (200 U/µL, 
Invitrogen). The samples were then incubated for 10 min at 25ºC, 60 min at 50ºC and 
finally 10 min at 70ºC to inactivate the enzyme, using a TPersonal thermocycler 
(Biometra). To discard genomic DNA contaminations, negative reactions were 
performed without SuperScript III.  
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To synthesise cDNA from total RNA enriched with small RNAs extraction the 
TaqMan®MiRNA Assays (Life Technologies) protocol was followed. For this reaction a 
total of 10 ng of RNA was used. The master mix for this reaction was composed by 1,5 
µL of dNTPs (10 mM), 1 µL of MultiscribeTM reverse transcriptase (50U/µL), 1,5 µL of 
reverse transcription buffer (10X), 0,19 µL of RiboLock RNase Inhibitor (40 U/µL, 
Thermo Scientific) and Nuclease-free water (Thermo Scientific) up to 7 µL. To this 
reaction was then added 5 µL of RNA (10ng) and 3 µL of RT primer (5X) and the 
samples were then mixed. The mixture was incubated on ice for 5 min before 
proceeding to the thermal cycling at 16ºC for 30 min, 42ºC for 30 min followed by 5 min 
at 85ºC for enzyme inactivation.  
All cDNA samples were stored at -20ºC. 
Quantitative Real Time PCR (RT-qPCR) 
For quantification of MCL1 mRNA isoforms the primer pairs designed (table 
1) were first optimized. The optimization consisted in performing the RT-qPCR 
reactions, as described below, using series of cDNA dilutions (1, 1:10, 1:100 and 
1:1000) to create a standard curve. In this standard curve the slope should be 
around -3.3, in order to obtain an ideal efficiency (90% to 110%). The efficiency 
was obtained through the following equations: E = 10 (-1/slope) and %E = (E-1) x 100. 
Each RT-qPCR reaction was performed using 10 µL of SYBR® Select Master 
Mix (Applied Biosystems, Life technologies), 0,25 µL of each primer (10 µM), 1 µL of 
the cDNA sample and nuclease-free water up to 20 µL. Reactions were performed 
using the StepOne Real-time PCR System (Applied Biosystems) thermocycler 
following the program recommended by the company.  
The reference gene chosen was the ribosomal gene 18S for all samples 61, 
62. The results were analyzed using the ∆Ct method (relative expression=2-(CT target 
gene – CT reference gene)), used to determine the expression of the target gene relative to 
the endogenous control, assuming the maximum efficiency (E=2), since the results 
do not suffered significant changes when the real efficiency was used.  
For quantification of the miRNAs expression, it was prepared a master mix 
containing 10 µL of TaqMan® Universal PCR Master Mix II, no UNG (Applied 
Biosystems, Life Technologies), 1 µL of 20X TaqMan® Small RNA Assay (Applied 
Biosystems, Life Technologies) and Nuclease-free water (Thermo Scientific) up to 18,7 
µL. To this mix it was added 1,3 µL of the prepared cDNA. Reactions were performed 
in the StepOne Real-time PCR System (Applied Biosystems) thermocycler using the 
recommended thermal cycling program (2 min at 50ºC; 10 min at 95ºC, and 40 cycles 
of 15 sec at 95ºC and 60 sec at 60ºC). The results were analysed with the previously 
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described ∆CT method using as reference gene the human U6 small nuclear RNA63.  
The codes of the TaqMan® probes used are described below (table 2). 
 
3’RACE (RAPID AMPLIFICATION OF CDNA ENDS) AND NESTED PCR 
The SMARTer™ RACE cDNA Amplification kit (Clontech) was used to 
synthesized 3´RACE cDNA, using SMARTScribeTM Reverse Transcriptase and 1 µg of 
total RNA, according to the manufacturer’s protocol. The first and nested 3’ RACE PCR 
reactions were done using the Phusion High-Fidelity DNA Polymerase (2U/µL – 
Thermo Scientific), following the manufacturer’s protocols. The forward primers were 
designed according to SMARTer™ RACE kit protocol’s specificities (table1). The 
products were then analysed by agarose gel electrophoresis (1,5%) stained with 
SybrSafe DNA gel stain (Invitrogen) and using the GeneRuler DNA ladder mix (Thermo 
Scientific). The desired bands from the agarose gel electrophoresis were cut and 
purified using the GRS PCR and Gel Band Purification Kit (Grisp). 
 
CLONING INTO TOPO VECTOR 
Previously to the TA-cloning procedure, we performed the addition of an 
adenine residue to the 3´-ends of the blunt gel purified PCR products by incubating 15 
min at 72 ºC the following mixture: 4 µL of the purified band, 0,5 µl of 5X GoTaq 
Reaction Buffer (Promega), 0,3 µL of dATP (2.5 mM) and 0,2 µL of GoTaq® DNA 
Polymerase (5 U/µl - Promega).  Cloning of the 3’RACE PCR purified bands was done 
using the TOPO TA Cloning Kit (Life technologies) according to the manufacturer’s 
instructions with minor modifications. Briefly, 4 µL of the mixture described above was 
added to 1 µl of Salt Solution (Life Technologies) and 1 µL of pCR2.1-TOPO vector 
(Life Technologies) and incubated for 30 min at 22ºC. The total volume of this mixture 
was transformed in 100 µl of Echerichia coli TOP10 competent cells. 
 
 
TRANSFORMATION OF COMPETENT BACTERIA 
Ten µL (or 6 µL in the case of the TA-cloning) of the plasmid ligation 
product were added to 100 µL of TOP10 chemically competent Echerichia coli 
(Invitrogen, Life Technologies). Cells were incubated on ice for 15 min, followed by 
a heat shock at 42 ºC for 90 seconds and put back on ice for more 5 min. LB 
medium (400 µL) was added and cells were incubated for 60 min in an orbital 
shaker at 37 ºC. The cells were then plated in LB plates with kanamycin (25 
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μg/mL) or ampicillin (100 μg/mL), according to the antibiotic resistance present in 
the plasmid used, and put at 37ºC overnight (ON).  
 
COLONY PCR 
In order to determine the colonies that incorporated properly the insert a 
colony PCR was performed. The PCR reaction was performed using 0,15 µL of 
GoTaq® DNA Polymerase (5 U/µl - Promega); 2 µL of 5X Green GoTaq® Reaction 
Buffer (Promega); 0,75 µL of MgCl2  (25 mM - Promega); 0,5 µL of each primer (10 
µM); 0,5 µL dNTPs (10 mM); and Nuclease-free water up to 10 µL. The plasmid 
template was obtained by a  stab of each colony with a tip that was then emerged in 
the reaction mix. The PCR reactions were carried out in TPersonal thermocycler using 
the following program: 5 min at 95ºC; 35 cycles of 1 minute at 95ºC, 30 seconds at 
56ºC, 30 seconds at 72ºC; and a last extension time of 7 min at 72ºC. The reaction 
product was then analysed by a 1% agarose gel electrophoresis. 
 
ACTINOMYCIN-D TREATMENT 
In this experiment seven time-point conditions were used (0, 0.5, 1, 2, 4, 6 
and 24 hours) and each condition was made in triplicates. Jurkat E6.1 cells were 
counted as described above and seed out at a confluence of 3x106 cells/mL in 24 
well-plates. To the time-point “0h” no Actimycine-D antibiotic (Sigma-Aldrich®) was 
added. To the other conditions 5 µg/mL of Actinomycin-D was added to the RPMI 
complete medium and the samples were then incubated at 37ºC. At each time- 
point, the samples were centrifuged at 300g for 5 min and, after removing the 
supernatant, the pellet was resuspended in 1 mL TRIzol. Posteriorly, the RNA 
extraction was performed as described above. 
 
PLUC CONSTRUCTS/PMIRGLO CONSTRUCTS 
 Each MCL1 3’UTR isoforms were amplified using as template the 
sequences cloned into the TOPO vector and specific primers (table 1). The 
forward and reverse primers used to amplify all isoforms had at its 5’ end a 
sequence for the SacI and SalI restriction enzymes (New England Biolabs), 
respectively. Using these primers all MCL1 APA-derived mRNA isoforms were 
amplified using the Phusion High-Fidelity DNA Polymerase (2U/µL – Thermo 
Scientific). For this reaction it was used 4 µL of 5X Phusion HF buffer; 0,4 µL of 
dNTPs (10 mM); 1 µL of each primer (10 µM); 0,2 µL of Phusion High-Fidelity DNA 
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Polymerase (2 U/µL – Thermo Scientific); 1µL of the plasmid used as template 
(250 ng); and Nuclease free water up to 20 µL. The amplification was performed in 
the TPersonal thermocycler using the following program: 1 minute at 98ºC; 25 
cycles of 10 seconds at 98ºC, 30 seconds at 56ºC, 2,5 min at 72ºC; and a final 
extension step of 7 min at 72ºC. The PCR products were analyzed by agarose gel 
electrophoresis (0,8%) as described above and then purified using QIAquick PCR 
Purification Kit (QIAGEN) according to manufacturer’s instruction. The purified PCR 
products and the plasmid “pLuc” were then digested with SacI and SalI restriction 
enzymes (New England Biolabs) and cloned as described below. 
 To clone the ~100-bp sequence of MCL1 3’UTR containing the putative binding 
sites for the selected miRNAs and those sites mutated two templates were used. To 
clone the wild type sequences it was used as template the pLuc constructs where 
MCL1 pA4 3’UTR were cloned and as backbone vector pmiRGLO (Promega). To clone 
the sequences containing the putative-binding sites mutated, it was used the pLuc 
plasmid where pA4 MCL1 3’UTR was cloned and where all miRNAs putative-binding 
sites were mutated by directed mutagenesis (described bellow). Once again, the 
primers used to amplify these sequences contained at their 5’end the sequences for 
SacI (primer forward) and SalI (primer reverse). For the amplification reaction it was 
used 0,2µL of GoTaq® DNA Polymerase (5U/µl - Promega); 4 µL of 5X Green GoTaq® 
Reaction Buffer (Promega); 1,5 µL of MgCl2  (25 mM - Promega); 1 µL of each primer 
(10 µM); 1 µL dNTPs (10 mM); 1 µL of the plasmid template and Nuclease-free water 
up to 20 µL. The PCR reactions were carried out in TPersonal thermocycler using the 
following program: 5 min at 95ºC; 25 cycles of 30 seconds at 95ºC, 30 seconds at 
56ºC, 30 seconds at 72ºC; and a last extension time of 5 min at 72ºC.The PCR 
products were analyzed by agarose gel electrophoresis (0,8%) as described above 
and then purified using QIAquick PCR Purification Kit (QIAGEN) according to 
manufacturer’s instructions. The PCR products and the plasmids used were then 
digested with SacI and SalI restriction enzymes (New England BioLabs). 
To perform the cloning of the sequences in pLuc and pmirGLO it was used 
the T4 DNA ligase (Thermo Scientific) according to the manufacturer’s guidelines. 
Posteriorly, the ligation product was transformed into competent cells as described 
above. Plasmid DNA extractions were performed using the PureLink™ Quick 
Plasmid Miniprep Kit (Life Technologies) and plasmids were sequenced in GATC 
Biotech company to confirm that they had the correct sequence.  
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DIRECTED MUTAGENESIS 
This procedure was performed to mutate the proximal pA sinals in each 
APA isoform to obtain the MCL1 3’UTR isoforms containing only the distal pA 
signals and to mutate the putative-binding sites of the miRNAs selected. Using this 
procedure it was possible to generate: the pA2 isoform with pA1 pA signal 
mutated, pA3 isoform with the pA1 and pA2 pA signals mutated, and pA4 isoform 
with pA1, pA2 and pA3 isoforms mutated. The pA4 construct was used to mutate 
the miRNAs putative-binding sites and this construct was then used as a PCR 
template to clone the ~100-bp sequence of MCL1 3’UTR containing the putative 
binding sites for the selected miRNAs into pmirGLO vector. 
This technique was performed according to the protocol described in Liu 
and Naismith 2008 64, with minor alterations. The primers were designed so that 
their 5’ends were complementary to each other and contained at the 
complementary region the mutations to be inserted. These primers pairs amplified 
all the plasmid sequence inserting only the desired mutation. Due to the template 
length it was used the Phusion High-Fidelity DNA Polymerase (2 U/µL – Thermo 
Scientific). For this reaction it was used 1,5µL of the plasmid template (15ng), 10 
µL of 5X Phusion HF buffer; 1 µL of dNTPs (10 mM); 2,5 µL of each primer (primer 
forward and primer reverse, 10 µM); 1,5 µL of Phusion High-Fidelity DNA 
Polymerase (2 U/µL – Thermo Scientific); and Nuclease free water up to 50 µL. 
After several optimizations, the PCR program used was the following: 1 minute at 
98ºC; 3 cycles of 10 seconds at 98ºC, 30 seconds at 70ºC, 5 min at 72ºC; 3 cycles 
of 10 seconds at 98ºC, 30 seconds at 68ºC, 5 min at 72ºC; 18 cycles of 10 
seconds at 98ºC, 30 seconds at 65ºC, 5 min at 72ºC; and a last extension step of 
10 min at 72ºC. The PCR products were analyzed by agarose gel electrophoresis 
(0,8%) as described above and then purified using QIAquick PCR Purification Kit 
(QIAGEN) according to the manufacturers’ instructions. To eliminate any remains 
of the parental plasmid, the purified PCR products were digested by using 2 µL of 
DpnI enzyme (New England Biolabs), 10 µL of 10X Cut Smart buffer, 49µL of the 
purified PCR product and Nuclease-free water up to 100 µL, for 2 hours at 37ºC 
followed by an inactivation time of 20 min at 80ºC. After, the PCR-generated 
mutant plasmids were transformed into competent cells as described above. All 
plasmids were sequenced in GATC Biotech company to confirm that they had the 
correct mutations. 
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TRANSFECTION ASSAYS 
 These procedures were performed in order to transfect the cells with the 
pLuc constructs containing the MCL1 3’UTR isoforms, the pmirGLO constructs 
containing the ~100bp sequences around the putative-binding sites for the 
selected miRNA, or to perform the overexpression of the selected miRNAs 
(Addgene Plasmid 21113: pcDNA3-miR17; Addgene Plasmid 21121: pcDNA3-miR29b; 
Addgene Plasmid 46672: pcDNA3.2 miR-1-1 reporter hsa-miR-92a-1). 
 HeLa cells were transfected using the Lipofectamine® 3000 reagent (Life 
Technologies) according to the manufacturer’s guidelines. Cells were placed on 
24-well plates at a concentration of 2x105 cells/mL and transfected when reached 
70%-90% confluency. Transfections were performed using in total 0,5 µg of 
plasmids. In the experiments to measure the Luciferase activity produced by the 
MCL1 3’UTRs isoforms two plasmids had to be transfected: pLuc (0,35 µg) and 
pCMV-Renilla (0,15 µg), once pLuc didn’t have the Renilla gene in its backbone. 
For pmiRGLO (has luciferase and renilla genes in its backbone) and miRNA 
overexpression experiments, 0,5 µg of plasmid were used. 
 
LUCIFERASE ASSAY 
 To perform the Luciferase assays the Dual-Luciferase® Reporter Assay 
(Promega) was used according to the manufacturer’s guidelines. The lysis process 
used in these experiments was the Passive Lysis procedure. Briefly, the cells were 
harvested and rinsed once with 1X PBS. Then, 100 µL of 1X Passive Lysis Buffer 
was added followed by 15 min shaking at room temperature. Next, 10 µL of each 
sample was added to a 96-well plate and 50 µL of LAR II was added to perform the 
firefly luciferase activity measurement. After, 50 µL of Stop & Glo® Reagent was 
added to perform the Renilla luciferase activity measurement. For the 
measurements of both firefly and renilla luciferase activities a Synergy 2 Multi-Mode 
Reader (Bio-Tek) was used. To achieve the final luciferase activity, the values 
obtained for luciferase were normalized to renilla. Final luciferase activity values 
represent the mean of three independent experiments. Each experiment was 
performed using duplicates. 
 
WESTERN BLOT 
To obtain the protein lysates needed to perform the western blot the medium from 
HeLa cells was removed and cells washed with PBS 1X. In the PBMCs and Jurkat 
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E6.1 cell line cells were first centrifuged for 5 min at 300 g, the supernatant was 
removed and cells washed with PBS 1X. 100 µL of Lysis buffer (10mM Tris-HCl pH 
7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40) with 1X proteases inhibitors (Roche) 
was added to the cells and incubated on ice for 15 min. The lysates were then 
transferred to an eppendorf and centrifuge for 10 min at 14,000g. The supernatant 
(containing the protein lysates) was then transferred to a new eppendorf. In order 
to perform the protein quantification the Bradford reagent (Bio-Rad) was used and 
absorvancy was read at 595 nm in a microplate spectrophotometer (µQuant™ - 
BioTek). After, 25 µg of protein (in a final volume of 10 µL) of each sample to 
which was added 10 µL of 2X loading buffer (with 5% β-mercaptoethanol) was 
boiled at 95ºC for 5 min. Then, the samples were loaded on a 12% SDS–PAGE gel 
and after 45 min at 200V, transferred onto a nitrocellulose membrane (Life 
Technologies) and subjected to western blot analysis. Briefly, membrane was 
blocked for 45 min with 5% non-fat milk in TBS with 0.2% tween and incubated 
overnight at 4ºC with a mouse monoclonal anti-human Mcl-1 antibody 
(eBioscience; 1:500 dilution). The horseradish peroxidase-conjugated goat anti-
mouse secondary antibody (1:20000 dilution; Santa Cruz Biotechnology) was 
added for 45 min. Between antibody incubations membrane was washed with TBS 
with tween 0,2% for 10 min four times. After the final wash, membrane was 
incubated with ECL for 5 min on dark and then revealed using a ChemiDoc™ XRS+ 
System instrument (Bio-Rad).  
 
FLOW CYTOMETRY 
Flow cytometry experiences were done using  1 x 106 cells per condition. 
Briefly, cells were centrifuged at 300g for 5 min at 4ºC and the supernatant was 
removed. Pellet was washed with 4 mL of 1X PBS and centrifuged at 300g for 5 
min at 4ºC. After supernatant has been removed, the cells were fixed with 2mL of 
2% paraformaldehyde during 20 min at room temperature in the dark. Cells were 
washed and resuspended in FACS buffer (1X PBS, 0.2% BSA, 0.1% NaN3). 
Afterwards, cells were incubated with anti-CD69-APC and anti-CD3-PE 
(Pharmingen) during 20 min at 4ºC in the dark. Following antibody incubation, cells 
were washed twice with FACS buffer and resuspended in 200 µL of FACS buffer 
for flow cytometry analysis. All experiments were then performed on the FACS 
CALIBUR (Becton Dickinson). 
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STATISTICAL ANALYSIS 
 To perform all statistical analysis the student t-test (for paired samples) was 
used. A p-value lower than 0,05 (*), 0,01 (**) or 0,001 (***) denoted the presence of a 
statistically significant difference. The analysis was performed using the GraphPad 
Prism® 6 software.  
Table 1 - List of primers used in this study 
Primers name Primers Sequence (5’-3’) Application 
MCL1-E2-RACE CTCGTAAGGACAAAACGGGACTGGCTAG 3’RACE PCR 
MCL1-E3-RACE AGGTGGCATCAGGAATGTGCTGCTG Nested RACE PCR 
cod-F-new AGGACCTAGAAGGTGGCATCAG RT-qPCR 
cod-R-new TAGATATGCCAAACCAGCTCCT RT-qPCR 
pA4 GCTTGGGGCAGTGAGGGCT RT-qPCR 
pA4 ACCACCTGCCTCCTCCTCC RT-qPCR 
MCL1-UTR-F -SacI TATGAGCTCCCTTACTGTAAGTGCAATAG Cloning 
MCL1-UTR-R-SalI CGAGTCGACGAATAAAAGATTTATTTTTTTTTCTC Cloning 
MCL1-pA1.2-R-SalI CGAGTCGACATAGAAACAAAACAGTAAGTATT Cloning 
MCL1-pA1.1-R-SalI CGAGTCGACCCAAGCCATCATTTTATAATTTATTAAG Cloning 
MCL1-pA0-R-SalI CGAGTCGACGGAGCACTCTTCCCATGTATT Cloning 
pA1mut-F CAAGAACTAGTACATGGGAAGAGTGCTCCC Directed mutagenesis 
pA1mut-R CATGTACTAGTTCTTGTTAGCCATAATCCTCTTGC Directed Mutagenesis 
pA2mut-F TGCTTAACTAGTTATGGAATGATGGCTTGGAAAAGC Directed Mutagenesis 
pA2mut-R TTCCATAACTAGTTAAGCAAACAAGGGATCAAATGTC Directed Mutagenesis 
pA3mut-F GTATGTCAACTAGGCAAATACTTACTGTTTTGTTTC Directed Mutagenesis 
pA3mut-R ATTTGCCTAGTTGACATACTAGGCTTAGACCTGT Directed Mutagenesis 
miR-92a mut-F TAAACTCCGTCGTTGACTTTTAACCAACCACC Directed Mutagenesis 
miR-92a mut-R GTCAACGACGGAGTTTACAGTAAGGGAGCTCG Directed Mutagenesis 
miR-29b mut-F CTAACCCTGATTCGATTATTAGGCTTGCTTGTTAC Directed Mutagenesis 
miR-29b mut-R ATAATCGAATCAGGGTTAGACTAGCCTGCTTTTC Directed Mutagenesis 
miR-320 mut-F TTCCTACGGAGTTCCCCTGCCATCCCTGAACTC Directed Mutagenesis 
miR-320 mut-R CAGGGGAACTCCGTAGGAATTGATATAAATATCTGTAG Directed Mutagenesis 
miR-17mut-F3 GGACCTAGAATCAAGCTATGTAGCTCTTCATTAGTC Directed Mutagenesis 
miR-17mut-R3 GAGCTACATAGCTTGATTCTAGGTCCTGAGAGATAC Directed Mutagenesis 
F_Luc_F AGGTCTTCCCGACGATGA RT-qPCR 
F_Luc_R GTCTTTCCGTGCTCCAAAAC RT-qPCR 
RL-F GCAGAAGTTGGTCGTGAGG RT-qPCR 
RL-R TCATCCGTTTCCTTTGTTCTG RT-qPCR 
92-f CTCGAGCTCCCTTACTGTAA Cloning 
92-R CGAGTCGACGAAGTTACAGCTTGGAGTCC Cloning 
29-f TATGAGCTCGGAGAGACATTTGATCCCTT Cloning 
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Primers name Primers Sequence (5’-3’) Application 
29-R CGAGTCGACCTAGGCTTAGACCTGTGTGT Cloning 
320-F TATGAGCTCGTTCTGCTCCCTCTACAGA Cloning 
320-R CGAGTCGACCAGTGCCAA AATCTAAAAGGG Cloning 
17-F TATGAGCTCCTTGATCATAAGCCGCTTA Cloning 
17-R CGAGTCGACCACTGGATTTGGCAGACA Cloning 
pmiRGlo_seq-F CATGACCGAGAAGGAGATCG Sequencing 
M13 F CCCAGTCACGACGTTGTAAAACG Sequencing 
M13 R CAGGAAACAGCTATGAC  Sequencing 
Note: Some of the sequencing and RT-qPCR primers were also used to perform the colony PCRs, according to the 
sequence used. 
 
 
Table 2 - List of the TaqMan probes used for the quantification of miRNAs expression 
Target Code 
miRNA-92a hsa-miR-29 - 000431 
miRNA-29b hsa-miR-29 - 000413 
miRNA-320 hsa-miR-320 - 002277 
miRNA-17 hsa-miR-17 - 002308 
U6 U6 - 001973 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
RESULTS AND DISCUSSION 
RESULTS AND DISCUSSION 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
RESULTS AND DISCUSSION 
Page 33 of 68 
Characterization of the MCL1 alternative polyadenylation pattern in human T 
cells 
MCL1 mRNA 3’ end mapping identified four APA-derived isoforms 
Using high throughput RNA-sequencing data, a collaborator of the Gene 
Regulation group at IBMC (Joel Neilson) identified MCL1 as a good candidate for 
studying APA in T cells as: 1) its expression is altered upon T cell activation originating 
transcripts with shorter 3’UTRs, 2) this event is conserved between primary human and 
mouse T cells and Jurkat E6.1 cell line and 3) this gene is important for T cell 
homeostasis and therefore MCL1 is a good model gene for studying APA in T cells. 
To attest the APA pattern of MCL1 identified by RNA-sequencing we first 
inspected the UCSC Genome browser (https://www.genome.ucsc.edu/). We observed 
that the previously described three MCL1 mRNA isoforms produced by alternative 
splicing contain the same 3’UTR sequence. In this browser four putative pA sites are 
predicted, all located in tandem in the 3’UTR of MCL1 (figure 10). However, at the 
beginning of this study in 2013, only the two most distal pA sites were described in the 
UCSC Genome browser.  
We extended our MCL1 in silico analysis to 3’end mapping by collecting all the 
deposited ESTs (expressed sequence tags) of human MCL1 available from multiple 
tissues at the UniGene database (ncbi.nlm.nih.gov/unigene/). From these, we selected 
the sequences (n = 350) that contained a pA signal or a pA tail for ESTs analysis in 
order to guarantee mRNAs with 3’ ends, and aligned these sequences against the 
MCL1 reference gene sequence (ENSG00000143384) to map their location. By this 
analysis (figure 11), we identified four APA-derived mRNA isoforms. For simplicity, we 
Figure 10 - MCL1 gene characterization by in silico analysis. This scheme illustrates the position of MCL1 
gene in chromosome one (red bar) and its genomic organization (under chromosome scheme). Blue or black 
boxes represent exons and the dashed lines between them represent introns. The thin blue or black boxes 
represent the 5’ UTR (at right) and the 3’UTR (at left). MCL1 produces three mRNA isoforms by the exclusion of 
part of exon one (upper scheme), inclusion of the three exons (middle scheme), or skipping of exon two (lower 
scheme). All mRNA isoforms present the same 3’UTR, which contain four regions that are predicted pA sites 
(green bars below genomic sequence). 
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decided to number these isoforms according to the position of the pA site in the MCL1 
3’UTR. Thereby we named pA1, pA2, pA3 and pA4 the mRNA isoforms produced by 
the recognition of the first, second, third and fourth pA signals, respectively. However, 
the pA2 pA site described by the human EST analysis does not match the one 
currently reported in the UCSC genome browser (green boxes in figure 10). Instead, 
the pA2 pA site identified by human EST analysis corresponds to the pA3 region 
reported in UCSC genome browser that also comprises pA3 of the EST analysis. The 
pA2 reported in UCSC genome browser was not identified in the EST analysis. These 
differences in reported mRNA isoforms may be due to differential expression of MCL1 
APA-derived mRNA isoforms in different tissues. What we observed from the human 
EST analysis is that pA4 mRNA is the isoform with more ESTs deposited sequences 
(Figure 11). 
 
 
 
 
 
 
 
To experimentally validate the results obtained with the in silico analysis, we 
performed 3’RACE and nested PCR (figure 12A and 12B, respectively) using primary 
human T cells (in a resting state and activated with PHA), Jurkat E6.1 (human cell line 
derived from an acute T cell leukemia) and HeLa cells (human cervical cancer cell 
line). Besides human primary T cells, we included HeLa cells in our analyses because 
as a cell line is easier to work and good to perform optimizations and Jurkat E6.1 cell 
line as its a good T cell model widely used. We observed that the APA pattern is the 
same in all the cell types analyzed (figure 12). Although 3’RACE is not a quantitative 
method, in figure 12A, in primary T cells, there is an increase in the intensity of the 
band correspondent to the MCL1 pA3 APA-derived isoform upon T cells activation. 
Figure 11 - Human MCL1 EST analysis. The pA4 is the mRNA isoform that has more deposited 
ESTs, followed by pA2, pA3 and pA1 isoforms.  
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Similarly to activated T cells (a proliferative condition), the intensity of the band 
correspondent to the pA3 mRNA isoform is also higher in Jurkat E6.1 and HeLa cell 
lines (oncological cell lines), in comparison to resting T cells (figure 12B). These 
evidences are in agreement to Sandberg et al.18 and Mayr et al.19 where they have 
shown an increase of transcripts with shorter 3’UTRs under proliferative conditions, 
such as activated T lymphocytes, and oncological conditions, respectively. 
 For further experiences we decided to investigate the four APA-derived mRNA 
isoforms: pA1, pA3 and pA4, identified both in the EST analysis and in 3’RACE, and 
the pA2 isoform, detected only by EST analysis. For that, we cloned the PCR products 
of the Jurkat E6.1 cell line produced by 3’RACE and obtained three of the four mRNA 
isoforms produced by APA represented in figure 11 (pA1, pA3 and pA4). The construct 
containing pA2 was generated by PCR from pA3. All construts were sequenced in 
order to map their pA signals and cleavage sites. Figure 13 summarizes the results 
obtained by the in silico analysis, 3’RACE and sequencing: all MCL1 APA-derived 
mRNA isoforms are represented as well as the sequence of the MCL1 3’UTR, where 
all four pA signals are highlighted and the mRNA cleavage sites are indicated by an 
arrow.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pA4 
pA3 
pA1 
12A 12B 
Figure 12 - mRNA isoforms of MCL1 produced by APA (blue arrows) by 3' RACE and Nested 
PCR. As observed in figure 12A APA gives rise to a two mRNA isoforms with about 3Kb and 1,5 Kb 
in length. By Nested PCR (figure 12B) it was possible to identify one more mRNA isoform (the 
shortest one) with about 0,3 Kb. (-) stands for no template negative control. 
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As described above the recognition of one pA signal over another is dependent 
of a variety of factors. However, one important factor to take into account in this 
mechanism is the strength of the pA signal. The most distal pA signals are usually 
described to be stronger, i.e., have the canonical AAUAAA pA signal, and thus tend to 
be more used65. Having this in consideration, our results from the EST analysis are in 
agreement with this concept, since pA4 has more ESTs deposited in comparison with 
the other pA signals. However, by sequencing the PCR bands of the 3’RACE we 
observed that all the four MCL1 pA signals have the AAUAAA canonical hexamer 
(figure 13). The presence of four strong canonical pA signals in the same gene is not a 
common event65. This particularity may impact the regulation of MCL1 APA-isoforms 
since it cannot be the strength of the pA signal by itself that dictates the choice of one 
pA signal over another.  It is therefore possible that in this case there are more 
intervenients in the choice of the pA sites. 
Figure 13 - Schematic illustration of MCL1 APA-derived mRNA isoforms, pA signals and 
cleavage sites used. The blue boxes highlight the four pA signals and the green arrows represent 
the sites where the mRNA cleavage takes place in order to produce each MCL1 APA-derived mRNA 
isoform. 
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MCL1 pA signals are highly conserved in mammals 
Given that the human MCL1 has four canonical pA signals, we went on to verify 
if this is the case for other mammals, revealing their importance throughout evolution. 
By the alignment of the MCL1 sequence in 10 representative mammalian species we 
observed a high degree of conservation of the MCL1 3’UTR with an overall pairwise 
identity of 65.5 % (figure 14). This degree of conservation on a non-coding region is 
striking, indicating a strong selective pressure throughout evolution to maintain 
sequences important for MCL1 function and regulation in different species. In 
accordance, one of the most important cis-regulatory elements present in the 3’UTR, 
the pA signals, are also highly conserved in these mammals: 96% for pA1, 90% for 
pA2, 97% for pA3 and 100% for pA4 (figure 14). Curiously, all species analysed have 
four pA signals on its 3’UTR. The majority of the species display 4 canonical pA signals 
and the ones that do not display the canonical pA signal present at least three 
canonical pA signals and a non-canonical one (mouse and Tasmanian devil) or two 
canonical and two non-canonical pA signals (elephant).  These results suggest that the 
MCL1 3’UTR is important for MCL1 functioning and regulation due to its high degree of 
conservation in different species. Moreover, it seems that the human MCL1 
orthologues also possess four pA signals possibly undergoing alternative 
polyadenylation, indicating that this mechanism is conserved for MCL1 in many 
mammalian species. 
96 % 90 % 100 %97 %
Figure 14 - The MCL1 3’UTR and pA signals are highly conserved in mammals. The multiple 
sequence alignment was made using Geneious v4.8 software. The pA signals are indicated by blue 
arrows above the alignment and a snapshot of the pA signal alignment, sequence logos and pairwise 
identities is represent bellow the overall alignment. All four pA signals are highly conserved among a 
variety of mammals, being pA4 the most conserved one (100%). 
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pA4 MCL1 mRNA isoform is highly regulated at the post-transcriptional level 
As it was described above, Sandberg et al.18 described that in proliferative 
conditions, specifically upon T cell activation, there is an increase in the expression of 
mRNAs with shorter 3’UTRs. This could be due through the usage of proximal pA sites 
or by down-regulation of the longest isoforms. Also, by RNA-sequencing our 
collaborator Joel Neilson identified MCL1 as one of the genes that undergoes 3’UTR 
shortening upon T cell activation, so we decided to investigate what is the process 
behind this mechanism. We started by quantifying the expression of MCL1 APA-
derived mRNA isoforms by RT-qPCR in primary T cells and PBMCs in resting and 
activated conditions (with PHA for 48 hours). We performed this experiment in PBMCs 
to check if this working model could be used instead of primary T cells, since PBMCs 
are cheaper to work and are very enriched in T lymphocytes.  
In order to confirm that the cells were efficiently activated we first analysed the 
phenotype of both T cells and PBMCs and then performed flow cytometry in PBMCs. 
As it can be observed in figure 15A, T cells and PBMCs were activated using PHA for 
48 hours since both produced large clusters of aggregated cells. We then quantified 
the activation in PBMCs using CD69 as a marker of activation and two time points: 24 
hours and 48 hours. As observed in figure 15B, the time point of 48 hours was the one 
that demonstrated to activate PBMCs at a higher level (~72% of CD69+ cells). From 
this figure it is also clear that the activation of T cells has a great contribution for the 
overall activation (68.4% of CD3+CD69+ cells). Also by analyzing these results we 
verified that from PBMCs isolation about 77% of the cells are CD3+, and thus T cells 
(figure 15 C). For that reason we decided to activate PBMCs using PHA for 48 hours.  
To measure the expression of MCL1 APA-derived mRNA isoforms by RT-qPCR 
two different primer sets were used: one that measures the expression of all APA-
derived isoforms (total RNA) that is localized in the coding region (named coding) and 
another primer pair that only measures the expression levels of the longest isoform 
(named pA4) (figure 16). Using these two primer pairs we could investigate how the 
pA4 MCL1 mRNA isoform expression is regulated in resting and activated conditions.
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Figure 15 - Optimization of T cells and PBMCs activation using PHA. A) Cells phenotype in both 
resting and activated conditions. The formation of cell clusters upon T cells/PBMCs activation with 
PHA for 48h is observed. B) Representative flow cytometry analysis showing that PBMCs present an 
increase in activated cells (CD69+ cells) when PHA was used for 48 hours. C) PBMCs contain 
approximately 77% of CD3+ cells demonstrating that they are very enriched in T cells. 
Figure 16 - Schematic illustration of the primer pairs used to measure the expression of MCL1 
APA-derived mRNA isoforms. The primer pair named coding measures the expression of all MCL1 
isoforms since is located on exon three, which is present in all isoforms. The primer pair named pA4 
only measures the expression of the longest isoform being located immediately upstream of the pA4 
pA signal. 
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Figure 17 shows the expression levels of MCL1 in primary T cells and PBMCs, in 
both resting and activated conditions, using the coding and pA4 primer pairs. We 
observe that although the expression of the measured isoforms in T cells being 10 
times smaller than in PBMCs, the pattern of expression is the same in these two cell 
types, which allowed us to use PBMCs in the following studies. Comparing the 
expression levels between resting and activated states, it is evident a statistically 
significant increase in the mRNA expression levels of all MCL1 isoforms upon T cells 
(17A) and PBMCs (17B) activation. On the contrary, in both cell types there are no 
differences in the expression of the MCL1 longest mRNA isoform (pA4) between the 
two cell states. Given that the expression of the pA4 isoform does not change but there 
is an increase in the expression of the coding region, this indicates that upon activation 
there is an increase in the shorter MCL1 APA-derived mRNA isoforms, confirming the 
previous results obtained for MCL1 by RNA-sequencing.  
 
Given that this experience was performed using total RNA (that includes both 
nuclear and cytoplasmic fractions), it is not possible to discriminate if the pattern of 
expression observed in figure 17 is due to APA, by more usage of proximal pA signals 
(mRNA regulation at the nuclear level), or to post-transcriptional regulation at the 
cytoplasmic level. To investigate this we performed a fractionation of nuclear and 
cytoplasmic RNA isolated from PBMCs.  
As it can be observed in figure 18A, the relative expression of pA4 mRNA 
comprises half of the coding relative expression in the nuclear fraction, suggesting that 
pA4 is the isoform that contributes more for the total MCL1 expression. This is in 
Figure 17 - MCL1 APA-derived mRNA isoforms relative expression. Relative expression of both 
coding and pA4 isoforms in resting (grey) and activated conditions (black) in primary T cells (left) and 
PBMCs (right), quantified by RT-qPCR; n=7 or 6 donors, respectively. Asterisks indicate significant 
values (p-value < 0.05* and p-value < 0,01 **). 
T cells 
n=7 
PBMCs 
n=6 
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agreement with the EST analyses performed above. Also, it is observed in the nuclear 
fraction a decrease in the expression measured by coding primer pair upon PBMCs 
activation. Besides not statistically significant, this decrease is also seen in pA4 
expression in the nucleus, and thus, once pA4 seems to be the isoform more 
expressed, the decrease in pA4 expression may have a major contribution in the 
overall decrease of MCL1 mRNA under PBMCs activation. Also, the decrease verified 
in pA4 expression upon PBMCs activation is higher than the decrease of the coding 
expression. This may indicate that upon cell activation the pA signals of the shorter 
isoforms are being recognized and more isoforms with shorter 3’UTRs are being 
produced.  
In the cytoplasmic fraction of activated PBMCs a decrease in pA4 relative 
expression is observed, suggesting that this isoform is regulated at the post-
transcriptional level in the cytoplasm of activated cells. In contrast, although not 
statistical significant, it seems that the total MCL1 expression (measured by coding 
primers pair) is higher in activated PBMCs than PBMCs in a resting state. As it has 
been described a role for MCL1 in T cells activation29, this could be a mechanism of to 
compensate the decreased levels of MCL1 mRNA seen in nucleus upon PBMCs 
activation. In order to understand in which cellular state the MCL1 APA-derived mRNA 
isoforms are more regulated in the cytoplasm, we measured the fold induction (figure 
18B) of cytoplasmic fraction in relation to total fractions. From this result we can 
conclude that MCL1 total mRNA (coding) levels are increased in the activated state in 
comparison to the resting state. In contrast, pA4 mRNA levels seems to be more prone 
to suffer down-regulation upon PBMCs activation.  
 
 
 
 
 
Figure 18 - Relative expression of fractionated MCL1 APA-derived mRNA isoforms. A.Relative 
expression of MCL1 APA-derived mRNA isoforms measured in the nucleus and cytoplasmic 
fractions. The expression was measured both in resting (grey) and activated (black) states. B. Fold 
induction of cytoplasmic fraction over total fractions (nuclear and cytoplasmic). A decrease in the 
coding and an increase in pA4 is observed upon PBMCs activation. Asterisks indicate significant 
values (p-value < 0.05*). For the fold induction (figure 18B) a donor from activated condition was 
eliminated due to its discrepancy. 
18A
. 
18B
. 
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Taken together the results shown in figure 18 indicate that upon T cell activation there 
is a shortening of the 3’UTR of MCL1 and that both APA at the nucleus, by the choice 
of proximal pA signals, and cytoplasmic post-transcriptional regulation mostly by the 
down-regulation of the pA4 longest isoform, have a role in MCL1 mRNA metabolism. 
 
Mcl-1 protein levels increase upon PBMCs activation 
To quantify Mcl-1 protein upon T cell activation, we performed western blot 
using protein extracts prepared from both Jurkat E6.1 and PBMCs (figure 19A and 
19B, respectively).  As described in Dzhagalov et al.29, we observe an increase in Mcl-
1 protein levels upon T cell activation. In accordance to what Mayr et al.19 described for 
oncogenes that isoforms with shorter 3’UTRs produce more protein due to its higher 
stability since these 3’UTRs have less binding-sites for negative regulators, a possible 
scenario is that the longest mRNA isoform of MCL1 is down-regulated in activated T 
cells in order to increase the production of Mcl-1 protein by translation of mRNAs with 
shorter 3’UTRs.  
This result together with the results obtained from RNA frationation assays may 
indicate that down-regulation of pA4 MCL1 APA-derived mRNA occurs in order to 
increase Mcl-1 protein levels in T cells states dependent of Mcl-1 expression, such as 
the activated state29. 
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Figure 19 – Mcl-1 protein levels in both Jurkat E6.1 cell line and PBMCs in resting and 
activated states. A)  An increase in Mcl-1 protein expression upon PBMCs and Jurkat E6.1 
activation is observed by western blot. B) Quantification of the western blot bands showing a ~2-fold 
increase of Mcl-1 in activated over resting states in the two cell types analysed.  
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MCL1 APA-derived mRNA isoforms have a half-life of four hours 
To determine MCL1 APA-derived mRNA isoforms stabilities, which could explain 
the differences observed in the relative expression of these isoforms, we performed an 
Actinomycin-D assay using the Jurkat E6.1 cell line.  Actinomycin-D inhibits RNA 
transcription by interfering with the action of RNA polymerase II and thus with the 
elongation process66. Therefore, this experiment is used to measure the stability of the 
mRNAs once the transcription was blocked. From this experiment (figure 20) we 
observed that there are no differences in the stability of the mRNAs as the half-life of all 
isoforms is approximately four hours. It has been described that  Mcl-1 protein and 
MCL1 mRNA have a very short half-life and that this depends on cell-type and cellular 
conditions23. Thus, we conclude that the stability of each isoform does not seem to 
have an impact in the relative expression of the MCL1 APA-derived mRNA isoforms in 
Jurkat E6.1 cells.  
 
 
 
 
 
 
 
 
 
 
 
pA3 MCL1 mRNA is the isoform that produces higher Mcl-1 protein levels 
In order to investigate the function of the different 3’UTRs of MCL1 APA-derived 
mRNAs in protein production we cloned the 3’UTRs from each isoform downstream of 
a luciferase reporter gene. To assure that each isoform was correctly expressed and 
used the corresponding pA signal at the end of the 3’UTR, all the proximal pA signals 
were mutated. By Luciferase assay (figure 21A) we show that pA4 is in fact the 
isoform that gives rise to less amount of luciferase activity and that the shortest 
isoforms are the ones originating more luciferase protein, in particular the pA3 isoform. 
We also performed a ratio between protein and mRNA levels in order to infer about the 
Figure 20 – MCL1 mRNA stability in Jurkat E6.1 cells after Actinomycin-D treatment. There are 
no differences in the stability of the different mRNA isoforms measured, being the half-life of all 
isoforms 4 hours. N=3 independent experiments. 
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translation efficiency for each mRNA (figure 21B). From this result it seems that pA3 
isoform seems to be the one more efficiently translated. In contrast, pA2 and pA4 
isoforms are the ones less efficiently translated.  
The decrease of luciferase protein production by pA4 could be also due to post-
transcriptional regulation of this long isoform. This result is in accordance with the 
results of the RNA fractionation (figure 18) and the western blots (figure 19) providing 
evidence that pA4 mRNA is down-regulated at post-transcriptional level to produce 
more protein by the shortest isoforms, which is once again in accordance to the Mayr 
et al.19 study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 - Luciferase assay for MCL1 APA-derived mRNA isoforms. A) Luciferase activity produced 
by the use of the 3’UTRs of each mRNA isoform of MCL1 generated by APA. Cells were transfected with 
luciferase reporter vectors containing the 3’UTRs of the four different APA-derived isoforms. In each 
construct the upstream pA signal was mutated. B) Translation efficiency measured by dividing protein 
levels by mRNA levels. Asterisks indicate significant values (p-value < 0.05*, p-value < 0.01**, p-value < 
0.001***, p-value < 0.0001****). This procedure was performed in three independent experiments using 
duplicate replicas. 
21A. 21B. 
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Characterization of post-transcriptional regulation of MCL1 APA-derived mRNAs 
by miRNAs 
MCL1 has a variety of putative-binding sites for miRNAs on its 3’UTR 
As previously observed in figure 18, we observed that pA4 MCL1 mRNA 
isoform is down-regulated at the post-transcriptional level in the cytoplasm, given that 
its expression significatively decreases under PBMCs activation. As described above, 
miRNAs are good candidates to be regulators in this process and for that reason we 
decided to study this possibility. By in silico analysis, we searched for putative-binding 
sites for miRNAs that could target MCL1. As we obtained a large number of putative 
miRNAs-binding sites on MCL1 3’UTR we decided to restrict our analysis using the 
following criteria: a) study the miRNAs that were predicted to target MCL1 in at least 
two of the databases used (https://www.targetscan.org/; 
https://www.miRNA.org/miRNA/home.do; https://www.mirtarbase.mbc.nctu.edu.tw/); 
b) study those that target a conserved sequence in mammals and c) choose the ones 
that were described to be expressed in T cells. According to these criteria, we selected 
three miRNAs to be studied: miRNA-17 that only targets the MCL1 longest APA-
derived isoform; miRNA-29b that binds pA3 and pA4 and that was previously described 
to regulate MCL1 in other cell types; and miRNA-92a that can target all MCL1 APA-
derived isoforms. We decided to also study miRNA-320 that, although its target site 
was not very conserved among the mammalian species analysed, is described to be 
expressed in T cells and is predicted to target MCL1 in two of the databases used.  
Figure 22 represents the location and sequence of each miRNA putative-binding site 
on MCL1 3’UTR.  
The conservation of the miRNAs binding sites on MCL1 3’UTR was verified by 
multiple sequence alignment of the 3’UTR of the ten mammalian species used for the 
in silico analysis shown in figure 14.  From this analysis it is clear that, with the 
exception of the putative-binding site for miRNA-320, all the other putative-binding sites 
are 100% conserved (figure 23). This suggests that these sequences have been 
important for MCL1 regulation throughout evolution and that the miRNAs that putatively 
bind these sequences could regulate MCL1 in other mammalian species as well.  
 Later on, we used the miRNAMap database 
(https://www.mirnamap.mbc.nctu.edu.tw/) to search for the reported expression of the 
selected miRNAs. We search for the expression in thymus since this tissue has high 
amounts of T lymphocytes. From figure 24 we can observe that all selected miRNAs 
are expressed in thymus. Also, it is clear that miRNA-92a is the one that is more 
expressed in thymus, followed by miRNA-17, miRNA-320 and miRNA-29b, 
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respectively. Thus, we decided to investigate the possible role of these miRNAs in 
MCL1 regulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22 - miRNAs putative-binding sites on MCL1 3'UTR. 3’ UTR sequence with the pA signals 
(AAUAAA sequence in blue) and the cleavage sites for each isoform (green arrows). The miRNAs 
putative-binding sites are represented by the outlined sequences: miRNA-92a in blue, miRNA-29b in 
orange, miRNA-320 in green and miRNA-17 in purple. 
miRNA-92a 
miRNA-29b 
miRNA-320 miRNA-17 
Figure 23 – Conservation of the miRNAs putative-binding sites on MCL1 3'UTR conservation. 
Red arrows represent the putative-binding sites of each miRNA. The putative-binding sites for miRNA-
92a, miRNA-29b and miRNA-17 are 100% conserved among a variety of mammalian species.  The 
putative-binding site for miRNA-320 presents a 56% of conservation among the studied species.  
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miRNA-17 and miRNA-320 expression increase upon T cell activation 
To experimentally determine the expression levels of the four selected miRNAs 
in our cell model, we measured their expression by RT-qPCR using TaqMan probes. 
Since we observed that MCL1 mRNA isoforms are differential regulated between 
resting and activated conditions (figure 18), we decided to measure miRNAs 
expression in these two cell conditions in human primary T cells. Moreover, we also 
performed this experiment in Jurkat E6.1 and HeLa cells given that they are suitable 
testing models. As Jurkat E6.1 is a cancer cell line, the proliferation rate and the 
miRNAs expression are themselves already altered, therefore in these cells, we did not 
quantify miRNAs expression in resting and activated conditions. 
As it can be seen in figure 25, all chosen miRNAs are expressed in T cells. 
However they are differential expressed: miRNA-92a is the one more expressed, 
followed by miRNA-320, miRNA-17 and miRNA-29b. These results are very similar to 
those obtained with the in silico analysis. In figure 25, it is also clear that both miRNA-
92a and miRNA-29b, are not differentially expressed between resting and activated 
Figure 24 - miRNAs expression in miRNAMap database. The highlighted bar demonstrates the 
expression of each miRNA in the thymus, the tissue where T lymphocytes mature. From these 
graphs we observed that miRNA-92a is the one more expressed, followed by miRNA-17, miRNA-320 
and miRNA-29b. 
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conditions. On the contrary, miRNA-17 and miRNA-320, that presumably target the 
longest MCL1 mRNA (pA4), are more expressed upon T cell activation. In accordance 
with the fractionation experience, where a decrease of pA4 expression is seen in 
activated conditions in the cytoplasmic fraction (figure18A), the increase of these two 
miRNAs upon PBMCs activation could be an indirect evidence that miRNA-17 and/or 
miRNA-320 may be involved in pA4 isoform down-regulation.  
The high expression levels of miRNA-92a and the increase in the expression of 
miRNA-17 during T cell activation are in accordance with previous studies. It has been 
previously shown that the cluster miRNA-17-92 is strongly induced after T cell 
activation being an important regulator of the rapid proliferation of these cells and also 
important in a variety of immune diseases67 68.  
In figure 25 it is also represented the expression of miRNA-92a, miRNA-29b 
and miRNA-17 in Jurkat E6.1 and HeLa cell lines. We verified that both miRNA-92a 
and miRNA-17 are highly expressed, which is in accordance with studies that 
described these miRNAs as being frequently amplified in some cancers types, since 
they belong to the miRNA-17-92 cluster described to be an oncomir, i.e., a miRNA 
associated with oncological conditions67, 68. From these results it can be concluded that 
the expression pattern of miRNA- 92a, miRNA-29b and miRNA-17 is the same in both 
cell lines.  
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Figure 25 - Relative expression of the selected miRNAs. A) The miRNAs that potentially target 
the longest MCL1 mRNA isoform (pA4), miRNA-17 and miR-320a, are the ones that increase their 
expression upon T cell activation. B) Expression of each miRNA in the two cell lines used in this 
study. It is clear that the expression pattern of these miRNAs is the same between Jurkat E6.1 and 
HeLa cells, two cancer cell lines. Asterisks indicate p value<0,05 * and p value<0,001 ***. 
 
25B. 
25A. miRNA-92a miRNA-29b 
miRNA-17 miRNA-320 
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miRNA-17 and miRNA-29b have a role in regulating MCL1 3’UTR 
To investigate the function of the chosen miRNAs in MCL1 regulation we cloned 
a fragment of MCL1 3’UTR containing the putative-binding sites of each miRNA (wild 
type) and the putative-binding sites of each miRNA mutated, using the luciferase 
reporter gene. After transfection of HeLa cells we compared their effect by luciferase 
assays. In figure 26 it is seen a statistical significant increase in luciferase activity 
when putative-binding sites of miRNA-17 and miRNA-29b are mutated. This indicates 
that they both target MCL1 mRNA at those specific sites (described in figure 22) and 
regulate MCL1 3’UTR once when the putative-binding sites of these two miRNAs were 
mutated an increase in luciferase activity was seen compared with the luciferase 
activity produced by the wild type construct. The increase of luciferase activity seen 
when the putative-binding site for miRNA-29b was mutated is in accordance with 
previous studies that have demonstrated a role for miRNA-29b in regulating MCL1, as 
previously described in the introduction42.  
On the contrary, when the putative-binding sites of miRNA-320 and miRNA-92a 
were mutated no differences were observed in luciferase activity comparing with the 
wild type. From this result we can infer that miRNA-320 and miRNA-92a do not have a 
role in regulating MCL1 3’UTR or another possibly is that its putative-binding site is not 
the one described above. In fact, MiRTarBase database 
(https://www.mirtarbase.mbc.nctu.edu.tw) described another putative-binding site for 
miRNA-320 in the beginning of the MCL1 3’UTR.   
 In the future we will focus on miRNA-17 as a good candidate to down-regulate 
the longest isoform to support the results observed in the RNA fractionation. 
The luciferase assays were also performed in the Jurkat E6.1 cell line (data not 
shown). Although being only preliminary results (n=1), we observed the same pattern 
of luciferase activity depicted on figure 26 for HeLa cells.  
One interesting finding from these experiments was that the overall luciferase 
activity values produced by the fragment of MCL1 3’UTR where miRNA-320 was 
supposed to bind was always very diminished (about five-fold decrease) when 
comparing with the other constructs. This may indicate that other cis-regulatory 
elements may be present in this region of MCL1 3’UTR and are somehow down-
regulating it. For that reason we searched for putative-binding sites for miRNAs and/or 
RBPs in that sequence (figure 27). We have identified four sequences where three 
RBPs can bind (https://www.rbpdb.ccbr.utoronto.ca/): RBMX, MBNL1 and ELAVL1; 
and one sequence where two miRNAs can bind: miRNA-16 and miRNA-15a 
(https://www.mirtarbase.mbc.nctu.edu.tw/). RBMX is a RBP known to be implicated in 
tissue-specific regulation of gene transcription and alternative splicing of several pre-
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mRNAs69. Also, MBNL-1 was described to regulate alternative splicing events and 
mRNA decay70, 71. ELAVL1 has been described to regulate APA in the brain and also to 
stabilize the mRNA with longer 3’UTRs72. Thus, this RBP does not seem to be the one 
that is exercising the  down-regulation of MCL1 in this sequence in HeLa cells. We then 
searched for the predicted expression of miRNA-16 and miRNA-15a. From the 
graphics depicted on figure 27 it is observed that miRNA-16 is highly expressed in the 
thymus. Although miRNA-15a is expressed, its expression levels are lower than those 
presented by miRNA-16. Also, some studies have demonstrated the role of these two 
miRNAs in down-regulating MCL173, 74. For that reason these two post-transcriptional 
regulators may be the ones more responsible for the decrease in luciferase activity 
produced by this specific sequence of MCL1 3’UTR. In this way it seems that all of 
these putative regulators, except ELAVL1, could be involved in the regulation of MCL1 
3’UTR through binding to this sequence and therefore explaining the lower values in 
the luciferase assays.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26 - Role of the four selected miRNAs on MCL1 3'UTR regulation. Luciferase activity 
produced by the wild type sequence of MCL1 3’UTR (black) and the Luciferase activity produced 
by the miRNA target sequence mutated (grey). Mutations in miRNA-17 and miRNA-29b target 
sites increases luciferase activity. Asterisk indicate p value < 0,05*. N=3 independent 
experiments.  
miRNA-92a miRNA-29b 
miRNA-17 miRNA-320 
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miRNA-17, miRNA-29b and miRNA-92a down-regulate Mcl-1 protein 
We then performed the overexpression of miRNA-17, miRNA-92a and miRNA-
29b in HeLa cells to study the effect of these miRNAs on endogenous Mcl-1 protein 
expression. We were particularly interested in testing miRNA-17, because it targets the 
MCL1 longest mRNA. However, we also tested miRNA-29b as a positive control in our 
experiment, because is well established that it down-regulates Mcl-1, and miRNA-92a 
to investigate its function in overall down-regulation of Mcl-1 expression. If this is the 
case, then miRNA-92a could be used in the future as a strategy to down-regulate Mcl-1 
in conditions where this protein is overexpressed, such as in some cancers as 
previously described. 
As it can been observed in figure 28 it is clear that miRNA-29b down-regulates 
Mcl-1 expression as previously described42. Also, another finding from this experience 
is that miRNA-92a also down-regulates Mcl-1 in similar levels as miRNA-29b. From the 
western blot (figure 28A and 28B), Mcl-1 expression is decreased by approximately 
30% in miRNA-17 and 60% in miRNA-92a and miRNA-29b overexpression conditions, 
in comparison to the control. However, when the overexpression of miRNA-17 was 
measured by RT-qPCR (figure 29) no differences were observed in relation to 
pcDNA3.1 (the backbone of the plasmids, used as a control). This experiment was 
repeated twice and the same result was obtained (data not shown). This could be due 
 
Figure 27 - In silico analysis to identify RBPs and miRNAs in the MCL1 3'UTR sequence used 
to test the role of miRNA-320. A. Three RBPs are described to have putative-binding sites in this 
sequence, indicated by coloured boxes. Also, two miRNAs (miRNA-16 and miRNA-15) were 
predicted to target this sequence, blue line. B. Predicted expression of miRNA-16 and miRNA-15 in 
thymus (highlighted bars). 
miRNA-320 miRNA-16 and miRNA-15 
27A. 
 
27B. 
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to the fact that this miRNA is already highly expressed in HeLa cells (figure 18) so it is 
possible that miRNA-17 levels are autoregulating themselves. 
From these results, we conclude that overexpression of miRNA-17, miRNA-29b 
and miRNA-92a down-regulate endogenous Mcl-1 protein expression. and thus all of 
them could be good candidates to regulate Mcl-1 expression.  So, miRNA-17 could be 
used by the cell as a strategy to down-regulate the longest MCL1 mRNA and promote 
the translation of the shortest isoforms that produce more protein, in situations when 
more Mcl-1 protein is required, such as during T cell activation. However, in figure 28A 
it is clear that miRNA-17 down-regulates endogenous Mcl-1 protein. A possible 
explanation for this is that HeLa cell is a tumor cell line and since Mcl-1 is already 
highly expressed in this cell line maybe the shortest isoforms are not being efficiently 
translated. Instead, in a situation where more Mcl-1 is needed, the down-regulation of 
the longest isoform by miRNA-17 overexpression could lead to an activation of the 
shortest isoforms translation, since in this case Mcl-1 is not highly expressed. To 
investigate this possibility, in the future, this experience has to be performed in PBMCs 
in resting and activated conditions. 
Figure 28  - Role of the selected miRNAs on endogenous Mcl-1 protein expression. A) Western 
blot showing that miRNA-17, miRNA-92a and miRNA-29b overexpression in HeLa cells lead to a 
decrease in the endogenous Mcl-1 protein expression. B) Quantification of Mcl-1 protein expression 
upon miRNAs overexpression by densitometry of the western blot bands demonstrating that miRNA-29b 
and miRNA-92a are the ones that lead to a higher downregulation of Mcl-1, followed by miRNA-17. 
28B. 
M
c
l-
1
 e
x
p
re
s
s
io
n
 u
p
o
n
 
m
iR
N
A
s
 o
v
e
re
x
p
re
s
s
io
n
 
(n
o
rm
a
li
z
e
d
 t
o
 α
-t
u
b
u
li
n
) 
28A. 
kDa 
 
55 
 
37 
α – tubulin 
 
Mcl-1 
RESULTS AND DISCUSSION 
Page 54 of 68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29 - miRNAs expression quantification after overexpression in HeLa cells. miRNAs 
expression was quantified by RT-qPCR after overexpression in HeLa cells. Black bars – miRNAs; 
grey bar – control.  Asterisks indicate p value < 0,05*. N= 3 experiments. 
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Characterization of MCL1 alternative polyadenylation pattern in human T cells 
From the results of this study we conclude that MCL1 undergoes APA 
generating four mRNA isoforms with different 3’UTR lengths.  From the RNA 
fractionation results it is observed a decrease in the expression of both coding and pA4 
mRNA in the nucleus, upon PBMCs activation. However, this decrease is more evident 
in the longest isoform (pA4) which is in agreement with our previous results and may 
indicate that proximal pA signals are preferentially used by APA, to produce shorter 
mRNAs, in this cell state. Another evidence from this result is that MCL1 is regulated in 
the cytoplasm at a post-transcriptional level given that a decrease in the pA4 isoform 
upon PBMCs activation is observed. This result suggests that this mRNA is silenced in 
the cytoplasm by the action of miRNAs. Also, although not statistical significant, there 
is an increase in total mRNA levels in the cytoplasm upon PBMCs activation 
demonstrating that the shorter isoforms account for this increase by possibly escaping 
regulation in the cytoplasm. From these evidences we can conclude that there is an 
increase of the shorter 3’UTRs upon cell activation both due to a switch in the pA signal 
recognition from the distal to a proximal one, and to the post-transcriptional regulation 
of the longest isoform (pA4) by miRNAs. 
Dzhagalov et al. 29 described that upon T cell activation more Mcl-1 protein is 
needed, and in fact we show that there is an increase in Mcl-1 protein upon activation 
of PBMCs and Jurkat cells. Also, Mayr et al.19 have demonstrated that the shortest 
mRNA isoforms of oncogenes give rise to more protein. According to these facts, one 
possible explanation for the RT-qPCR results is that two mechanisms occur 
simultaneously in order to increase the Mcl-1 protein levels upon cell activation. First, 
the pA4 isoform is silenced in the cytoplasm by miRNAs upon PBMCs activation and 
second the shortest isoforms, the ones demonstrated to be more effyciently translated 
by luciferase assays, specially pA3, are less prone to regulation and thus more coding 
mRNA is measured upon cell activation.  
Taken together our results indicate that MCL1 mRNA levels produced by the 
longest isoform are regulated in the cytoplasm by miRNAs upon PBMCs activation. As 
it has been previously described that Mcl-1 is needed to promote activation of T cells, 
we propose that this is a mechanism used by the activated cells to promote the 
translation of the shortest mRNA isoforms, and consequently, produce higher amounts 
of Mcl-1 protein.  
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Characterization of the post-transcriptional regulation of MCL1 APA-derived 
mRNA isoforms by miRNAs 
As it was clear that MCL1 undergoes APA and that the four mRNA isoforms 
produced are differentially regulated under resting and activated cell conditions, we 
decided to identify the miRNAs that could be exerting a function in this control. All the 
four miRNAs chosen in this study are expressed in T cells and miRNA-17 and miRNA-
320, the ones that target the longest mRNA isoform, increase their expression upon T 
cell activation. For that reason these two miRNAs were used as two potential key 
regulators of the MCL1 longest mRNA upon T cell activation. From the selected 
miRNAs, miRNA-92a was the one more expressed in T cells both in resting and 
activated conditions. This result, together with the increase of miRNA-17 upon T cell 
activation is in accordance to what is already described for the miRNA-17-92a cluster 
that is known to be involved in proliferative conditions and highly expressed upon T 
cells activation67, 68.  
Using reporter assays, we identified miRNA-17 and miRNA-29b as targeting 
MCL1 3’UTR since when the putative-binding sites for those miRNAs where mutated 
an increase in luciferase activity was observed. On the other hand no statistical 
significant changes were seen when the same analysis was performed for miRNA-92a 
and miRNA-320. Since we have shown a decrease in Mcl-1 expression upon miRNA-
92a overexpression (figure 28), it is possible it is targeting MCL1 3’UTR in another 
site, different from the one we mutated in our experiments. It is worth noting that there 
is a general decrease in luciferase activity when the fragment surrounding the miR-320 
putative-binding site was used. This indicates that this fragment could have important 
cis-elements to which regulators of MCL1 3’UTR may bind. It will be interesting to 
further investigate this possibility in future works.  
 At the endogenous Mcl-1 protein level it is clear that miRNA-17, miRNA-29b 
and miRNA-92a overexpression induced protein downregulation. miRNA-29b was 
already described to down-regulate Mcl-1 expression, however, we showed that both 
miRNA-17 and miRNA-92a also down-regulate endogenous Mcl-1. As in some 
pathologies Mcl-1 is overexpressed, such as in cancers and since the miRNA-17-92a 
cluster is described to be important in T cells biology the use of these miRNAs  could 
be a therapeutic strategy in some hematopoietic cancers in order to decrease cancer 
cell survival. 
  
 Overall, in this thesis we dissected some of the molecular mechanisms involved 
in MCL1 regulation and illustrated the interplay between APA and miRNA silencing that 
regulates Mcl-1 expression in human T cells. 
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Working Model 
 According with the results presented in this thesis we proposed a working 
model for MCL1 APA-derived isoforms regulation in T cells. In this model we propose 
that in the nucleus, in T cells resting, there is a preferential usage of the distal pA signal 
(pA4). In activated T cells there is a decrease in the recognition of the pA4 signal and 
thus the MCL1 expression is predominantly due to the transcription of the shortest 
isoforms. In the cytoplasm, the longest isoforms are post-transcriptional down-
regulated by miRNA-17 in activated T cells. Therefore the shortest isoforms, the ones 
more efficiently translated, are the ones more expressed in this cell condition leading to 
an increase of Mcl-1 protein expression upon T cell activation.  
 
 
 
 
 
 
Figure 30 - Working model for MCL1 APA-derived isoforms regulation in T cells. Schematic 
representation of APA and post-transcriptional regulation role in MCL1 and Mcl-1 expression in T 
cells. 
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Future perspectives 
In future work it will be necessary to repeat the luciferases assays in resting and 
activated PBMCs, to characterize both the protein levels that each MCL1 APA-derived 
mRNA isoforms produces and also to study the miRNAs, in a more physiological 
context. The overexpression of the selected miRNAs should be also performed in 
PBMCs in both resting and activated states in order to understand if, in fact, the down-
regulation of the longest isoform could lead to an increase in Mcl-1 protein levels. 
Simultaneously, it will be important to quantify MCL1 APA-derived mRNA isoforms by 
RT-qPCR in the cells where the overexpression of miRNA-17 was performed. This 
would further confirm if miRNA-17 down-regulates the mRNA levels of MCL1 longest 
isoform. Also, it would be important to perform luciferase assays with overexpression of 
miRNA-17 and inhibit miRNA-17. With these experiments we could further validate our 
idea that miRNA-17 is involved in Mcl-1 biology. 
It will be important to understand how MCL1 APA impacts on T cell biology, by 
investigating its effect in proliferation, cellular viability and apoptosis, and also to 
disclose what happens to these cellular processes under miRNA-17 overexpression 
and inhibiton. 
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